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SUMMARY
There is still debate about the relationship between fat accumulation and mitochondrial
function in nonalcoholic fatty liver disease. It is a critical question since a proportion of
individuals with steatosis progress to steatohepatitis. This thesis is focused on defining i)
the effect of triglyceride accumulation and reactive oxygen species (ROS) on
mitochondrial function ii) the contribution of triglyceride, ROS and subsequent
mitochondrial impairment to the metabolism of energy substrates iii) the effect of the
intracellular antioxidant, N-acetylcysteine, on hepatic mitochondrial function and
metabolic alterations associated with human steatohepatitis iv) the effect of different
free fatty acids species on ROS production and subsequent metabolic response in
hepatocytes.
To address these questions, we designed in vitro models using human hepatoblastoma
C3A cells treated with various combinations of oleate, octanoate (O), lactate (L),
pyruvate (P) and ammonia (N) acutely or for 72 hours, before measurements of
triglyceride concentration, cell respiration, ROS production, mitochondrial membrane
potential, ketogenesis and gluconeogenesis, metabolomics analyses, confocal and
electron microscopy.
Acutely, LPON treatment enhanced mitochondrial respiration and ROS formation.
After 72 hours, despite the similarities in triglyceride accumulation, LPON treatment,
but not oleate, dramatically affected mitochondrial function as evidenced by decreased
respiration, increased mitochondrial membrane potential and enhanced ketogenesis.
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Importantly, this was associated with increased markers of oxidative stress and
enhanced gluconeogenesis. Furthermore, reduction in triglyceride with metformin did
not improve mitochondrial function. By comparison, respiration and ROS formation
remained unperturbed with oleate. The addition of the antioxidant N-acetylcysteine
prevented mitochondrial dysfunction and reversed metabolic changes seen with LPON,
strongly suggesting ROS involvement in mediating mitochondrial impairment.
Our data indicate that increased ROS formation, rather than cellular steatosis per se,
impairs mitochondrial function. Thus, reduction in cellular steatosis may not always be
the desired outcome without concomitant improvement in mitochondrial function
and/or a decrease in ROS formation.
17
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1.1. Nonalcoholic fatty liver disease
Nonalcoholic fatty liver disease (NAFLD) has emerged as the most common liver
disease in the developed world. It is a condition characterized by intracellular
triglyceride accumulation within the liver that potentially, in the presence of
inflammation, can progress to steatohepatitis (1-3). Similar to other chronic liver
disorders, nonalcoholic steatohepatitis (NASH) can culminate in fibrosis or cirrhosis of
the liver. Current estimates are that ~20% of the general United States population has
NAFLD, with the prevalence in the morbidly obese population estimated as 75-92% (4-
7). The true prevalence of NAFLD is likely to be higher, because most people in earlier
stages of the disease are asymptomatic and remain undiagnosed. Importantly, this
prevalence is expected to escalate mirroring the global epidemic of obesity and Type 2
diabetes.
The relationship between dietary fat, hepatic steatosis and/or cirrhosis has been
recognised for ~60 years. For several decades, its clinical significance was uncertain;
hepatic steatosis (in the absence of alcohol excess) was presumed to be a benign and
inconsequential condition (8, 9). This long-held view was challenged when the concept
of NAFLD came to fore in the 1980s. The term was coined by Ludwig et al. to denote
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histological changes suggestive of steatohepatitis in liver biopsy specimens from 20
individuals who were mosdy obese or with diabetes, and without significant alcohol
intake (10). Similar to that seen with alcoholic hepatitis, these histological findings were
characterized by the presence of striking fatty accumulation with concomitant lobular
hepatitis, focal necrosis and inflammatory infiltrates. Importantly, these changes were
accompanied by evidence of fibrosis and cirrhosis (10).
The findings by Ludwig et al. became the impetus to numerous studies, which now have
firmly defined NAFLD as a continuum of histological changes encompassing simple
steatosis in its most benign form to its most advanced form, cirrhosis. It is estimated
that nearly 35% among those with steatosis would progress to steatohepatitis. Of these,
a considerable proportion would develop fibrosis and cirrhosis (with its attendant
complications such as hepatic failure and portal hypertension) (11, 12). More
importandy, 4-27% of individuals with NASH-induced cirrhosis ultimately would
progress to develop hepatocellular carcinoma (13).
Besides these liver complications, NAFLD is associated with insulin resistance and may
be an independent risk factor for cardiovascular disease (14). Indeed, NAFLD has been
proposed to be the hepatic component of metabolic syndrome. It is well established
that insulin resistance is a prerequisite for its development (15). Thus, it is not surprising
that diabetes is frequently encountered among individuals with NAFLD (16, 17).
Conversely, the prevalence of NAFLD among individuals with Type 2 diabetes is
estimated to be ~70% (18). In addition, the presence of diabetes is associated with more
severe and rapidly progressing fibrosis (19, 20).
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1.2. Pathogenesis of hepatic steatosis
The molecular events that lead to intrahepatic triglyceride accumulation are poorly
understood but may involve interplay of a number of factors; 1) increased free fatty acid
uptake, 2) elevated de novo synthesis of fatty acids, 3) impaired lipoprotein synthesis or
secretion, and/or 4) reduced fatty acid oxidation. These factors result in an imbalance
between triglyceride uptake and removal. Under physiological conditions, there are two
potential sources of fat in the liver; first, hepatic fat may arise from uptake of free fatty
acids (FFA) from the circulation. Circulating FFA can come from dietary derived
chylomicron particles, lipoprotein remnants or from lipolysis of adipose tissue. Second,
the liver has the capacity to synthesize fatty acids from other substrates (notably
carbohydrates), in a process of de novo lipogenesis. Within the liver, FFA are esterified
into triglycerides, which can then be stored as lipid droplets within hepatocytes or
assembled with apolipoprotein B 100 (ApoB) to be secreted into the blood as very low
density lipoprotein (VLDL). Additionally, triglycerides can be hydrolyzed into FFA,
























Figure 1.2. Intrahepatic triglyceride accumulation in NAFLD.
There are two potential sources of fat in the liver. First, hepatic fat may arise from
uptake of free fatty acids (FFA) from the circulation. Circulating FFA can be derived
from dietary chylomicron particles, lipoprotein remnants or from lipolysis of adipose
tissue. Second, hepatic fat may also arise from de novo lipogenesis. Within the liver, FFA
are esterified into triglycerides, which can then be stored as lipid droplets or secreted as
very low density lipoprotein (VLDL). Triglycerides can be hydrolyzed into FFA, which
can be channeled towards |3-oxidation. Imbalances between uptake (increased FFA
uptake or elevated de novo synthesis) and removal (impaired lipoprotein
synthesis/secretion or reduced oxidation) lead to hepatic triglyceride accumulation.
PPAR; peroxisome prohferator-activated receptor; ChREBP, carbohydrate response
element-binding protein; CPT-1, carnitine palmitoyl transferase-1 and SREBP-lc, sterol
regulatory element-binding protein-lc.
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Liver fat accumulation in NAFLD is largely influenced by systemic availability of
circulating FFA with minor contributions from de novo lipogenesis, FFA oxidation and
lipoprotein secretions (21, 22). In an elegant study employing stable isotope tracers,
Donnelly et al. demonstrated that ~60% of hepatic triglycerides resulted from FFA
delivery to the liver (22). Peripheral insulin resistance is likely to enhance the portal
concentration of FFA. Loss of insulin sensitivity in the adipose tissue results in failure
to suppress lipolysis, liberating FFA into the circulation. Consequently, hepatic FFA
uptake is increased, proportional to the portal concentration of FFA (23). The
expression of genes involved in FFA uptake such as ScarbX and Cdi6 has been shown to
be upregulated in NAFLD (24).
Increased peripheral insulin resistance is characterized by hyperinsulinaemia and
hyperglycemia. Insulin, a powerful instigator of de novo lipogenesis, acts by stimulating
the activity of key lipogenic transcription factors, such as peroxisome proliferator-
activated receptor gamma (PPARy), carbohydrate response element-binding protein
(ChREBP), and sterol regulatory element-binding protein-lc (SREBP-lc) (25-27).
Similarly, hyperglycemia contributes to de novo lipogenesis through the formation of
acetyl-coA, as well as through the activation of lipogenic transcription factors (28, 29).
Indeed, individuals with NAFLD have an elevated de novo lipogenesis compared with
healthy subjects (22, 30).
The capacity of lipid storage in the liver is limited. FFA oxidation and VLDL secretion
serve as measures to remove excess FFA from the liver. The role of decreased (3-
oxidation or altered VLDL secretion in the pathogenesis of NAFLD remains uncertain.
Diminished VLDL secretion is thought to be a feature of steatohepatitis rather than that
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of simple steatosis (31). Similarly, steatosis is associated with increased (3-oxidation but
this remains unaltered with the onset of steatohepatitis (24, 32). In support of this, the
expression of genes involved in mitochondrial (3-oxidation is unchanged in NASH (21).
Hepatic lipid accumulation diminishes with the progression of steatohepatitis to
cirrhosis, a phenomenon that has often been described as 'burnt-out NASH' (33). Thus,
the appearance of an established nonalcoholic steatohepatitis/cirrhosis is largely
indistinguishable from other causes of cirrhosis. The mechanism involved is yet to be
delineated but is thought to be predominantly attributable to the downregulation of
lipogenic transcription factor SREBP-lc, which diminishes the de novo lipogenesis (34).
It has also been proposed that the overwhelming oxidative stress and the subsequent
hepatocellular necrosis can promote the release of cellular lipid (35).
1.3. Progression to steatohepatitis and oxidative stress
As previously discussed, the progression to steatohepatitis occurs in approximately one
third of individuals with steatosis (11). A considerable proportion of those with
steatohepatitis would advance insidiously to fibrosis/cirrhosis. The presence of diabetes,
metabolic syndrome, raised body mass index, older age and the presence of
inflammation in the initial biopsy are among the risk factors identified for the
progression to fibrosis (12, 19, 36). The prognosis of steatohepatitis-induced cirrhosis is
poor; a third would develop significant liver related morbidity and mortality within a
relatively short period (37).
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Thus, dissecting the events involved is crucial. The 'two-hit' model proposed by Day
and James provides a conceptual framework of the pathophysiology of steatohepatitis.
According to this model, intracellular triglyceride accumulation is the first 'hit'. This
increases the susceptibility of hepatocytes to an interplay between oxidative stress and
cytokines or 'the second 'hit' (38).
Human and experimental NAFLD are characterized by chronic oxidative stress (39, 40).
Oxidative stress is the result of an imbalance in the formation of prooxidant (reactive
oxygen species (ROS)) and antioxidant (41). This disequilibrium is such that it favours
the generation of prooxidants. ROS (superoxide, hydrogen peroxide and hydroxyl) are
highly reactive molecules derived from oxygen formed mainly in the mitochondria as
the byproduct of respiration. Although ROS have been implicated in many
pathophysiological processes, they are also important signaling molecules (42-44).
Under physiological condition, ROS formation is tightly regulated. Liver is endowed
with antioxidants such as mitochondrial superoxide dismutase (MnSOD), glutathione
peroxidases (GPX), catalase and peroxiredoxins, which are extremely efficient in
counteracting the superfluous ROS (45).
Cellular damage can occur when ROS overwhelm the capabilities of antioxidants. In the
liver, ROS can mediate hepatocyte injury by three potential mechanisms. First, ROS
induce direct oxidative modification of macromolecular structures including lipid,
protein and DNA (46). For example, ROS can instigate lipid peroxidation leading to the
formation of reactive aldehydes such as 4-hydroxynonenal (4-HNE) and
malondialdehyde (MDA). Second, ROS can initiate a cascade of proinflammatory
cytokines such as tumor necrosis factor (TNF)-a, transforming growth factor (TGF)-|3
25
and interleukin (IL)-8, which in turn, can promote the release of inflammatory
mediators and activate the stellate cells (47). These cytokines in concert with the reactive
aldehydes can generate further ROS thus perpetuating a vicious cycle (48). Third, ROS
are known to induce stress pathways such as protein kinase C (PKC), mitogen-activated
protein kinase (MAPK), jun N-terminal kinase (JNK), nuclear factor-kb (NF-kB)).
There is strong evidence to support increased prooxidant in steatohepatitis. For
example, the expression of cytochrome P450 2E1 (CYP2E1), an enzyme with
substantial prooxidant activity, has been shown to be upregulated in steatohepatitis (49).
The activity of CYP2E1 is significantly higher in steatohepatitis than in simple steatosis
(50). Similarly, the level of 8-hydroxydeoxyguanosine, a marker of DNA oxidative
damage, is higher in NASH, but is rarely present in steatosis, and is undetectable in
normal liver (51). Its expression correlates with hepatic necroinflammatory activity. The
intermediates of lipid peroxidation are also increased in steatohepatitis suggesting
heightened oxidative process (32, 51, 52). Similarly, pro-inflammatory pathways such as
JNK and NF-kB are upregulated and can potentially trigger the release of cytokines (53,
54). Indeed, the levels of cytokines such as TNF-a, IL-6, and IL-8 are raised in
individuals with steatohepatitis (55, 56). Diminished antioxidant activity coupled with
glutathione depletion in human steatohepatitis can aggravate these inflammatory
activities further (50, 57, 58). Importantly, mitochondrial alterations known to occur in
steatohepatitis can perpetuate the release of ROS, thus bolstering the already enhanced






Figure 1.3. The mechanisms of reactive oxygen species mediated injury in the
hepatocyte.
ROS are byproducts of normal respiration. An imbalance between ROS formation and
antioxidant results in oxidative stress. Under this condition, ROS can alter
macromolecular structures including mitochondrial DNA and mitochondrial respiratory
chain. ROS can also induce lipid peroxidation as well as instigating the release of
cytokines, which in turn can activate various pathways leading to fibrosis, cell death and
inflammation.





1.4. Mitochondria and ROS formation
1.4.1. Mitochondrial structure
Mitochondria are cellular organelles responsible for ATP production in all eukaryotes. A
double-layered membrane encloses each mitochondrion. The inner layer invaginates
into the matrix to form a shelf-like structure known as cristae (Figure 1.4.1).
Mitochondria do not exist as an individual organelle but comprise dynamic networks
that constantly undergoing fission and fusion (60). Mitochondria are unique in that they
possess a separate genome. Mitochondrial DNA (mtDNA), a circular double-stranded
DNA molecule located in the matrix, encodes 13 of the respiratory chain polypeptides.
The presence of mtDNA has become the crux of the endosymbionts hypothesis of its
origin. This hypothesis posits that mitochondria are derived from a-proteobacteria that
formed a symbiosis with archaebacteria ~2 billion years ago (61).
Aside from ATP formation, mitochondria regulate many crucial pathways including cell
cycle, cell death and energy substrates oxidation. Metabolic pathways such as TCA cycle,
urea cycle and (3-oxidation occur in a close proximity to the respiratory chain within the
mitochondria to allow a precise ATP regulation. However, the constant superoxide
formation as the byproduct of respiration can predispose mitochondria to ROS
mediated injury. Mitochondrial structural and functional abnormalities in steatohepatitis
such as mtDNA depletion, decreased respiratory chain activity and diminished ATP are
strongly linked to the oxidative stress (32, 62-64). Indeed, some have suggested that
NAFLD might be a mitochondrial disease.
28
Figure 1.4.1. Mitochondrial structure viewed under electron microscopy.




Carbohydrates (glucose) and lipids (FFA) are the principal energy substrates in many
living organisms. Amino acids are also an energy substrate, however, following
deamination, they converge into the carbohydrate oxidative pathways. The coupling of
substrate oxidation to the ATP formation by mitochondrial respiration i.e. oxidative
phosphorylation, allows the fine-tuning to match the energy substrate oxidation to the
ATP formation and energy demand.
The uptake of glucose into the hepatocytes occurs passively across the concentration
gradient through a transmembrane carrier protein, glucose transporter 2 (GLUT2).
Within the cytoplasm, glucose is phosphorylated by hexokinase to glucose 6-phosphate,
which then enters glycolysis culminating in the formation of pyruvate. In turn, pyruvate
is transported into the mitochondria and decarboxylated resulting in the formation of
acetyl-coA.
Similarly, the uptake of FFA by fatty acid transporters such as fatty acid translocase
(FAT/CD36) into the hepatocytes is proportional to its portal concentration. Fatty acid
is activated by acyl-coA synthetase into fatty acyl-coA in the cytosol. Fatty acyl-coA is
then transferred (for example, by carnitine palmitoyl transferase) into the mitochondria
to undergo (3-oxidation, leading to acetyl-coA formation. Thus, acetyl-coA is the point







Figure 1.4.2.1. Glucose and free fatty acid metabolism.
Glucose transporter 2 (GLUT2) and fatty acid transporters such as fatty acid translocase
(FAT/CD36) mediate glucose and FFA uptake into the hepatocytes respectively. Within
cytoplasm, glucose enters glycolysis culminating in the formation of pyruvate, which is
converted into acetyl-coA in the mitochondria. Similarly, FFA is activated in the
cytoplasm into FFA acyl-coA, which is transported into the mitochondria for (3-
oxidation resulting in the formation of acetyl-coA. In turn, acetyl-coA enters the TCA
cycle. The turnover of TCA cycle generates NADH and FADH2 for mitochondrial
respiratory chain
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The oxidation of acetyl-coA by the TCA cycle results in the formation of electron
carriers, NADH and FADH2, destined for the respiratory chain. The electrons from
NADH are released to Complex I (or Complex II for FADH^ of the respiratory chain
and these electrons are subsequently transferred across a series of donors and acceptors.
The passage of electrons continues until they are passed on to oxygen, the final electron
acceptor (Figure 1.4.2.2).
The movement of electrons across the respiratory chain releases energy. This energy is
harnessed by Complex I, III and IV and is utilized to extrude protons against the
concentration gradient into the mitochondrial intramembrane space. This generates an
electrochemical gradient across the inner mitochondrial membrane or proton motive
force (65). Proton motive force is a major determinant of the mitochondrial membrane
potential (A Wm) and is pivotal in ATP synthesis. It fuels the formation of ATP from
ADP and inorganic phosphate using the energy released from the proton movement
down the concentration gradient into the matrix through the ATP synthase (Figure
1.4.2.2). FADH2 yields 40% less ATP than NADH. The reason is that NADH releases
electron to Complex I thus the passage of electrons involves three proton-pumping
complexes (complexes I, III and IV) whereas electrons from FADH2 are released at
Complex II and the subsequent forward movement of electrons only involves two sites
for proton extrusion (complexes III and IV).
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Outer membrane
Figure 1.4.2.2. Oxidative phosphorylation.
Mitochondrial respiratory chain is a series of electron acceptors and donors. There are
four transmembrane enzyme complexes embedded in the inner membrane (Complex I
(NADH dehydrogenase), Complex II (succinate dehydrogenase), Complex III
(cytochrome bcx complex) and Complex IV (cytochrome c oxidase) in addition to
coenzyme Q (ubiquinone) and cytochrome c, which shuttle electrons to Complex III
and IV, respectively. The movement of electrons (red arrows) is coupled with the
extrusion of protons (purple arrows) from Complex I, III and IV into the
intermembrane space. This generates proton gradient, which drives the ATP formation
(brown arrow). The electrons are subsequently reduced by oxygen, the final electron
acceptor, to form water. Q, coenzyme Q; Cyt c, cytochrome c.
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1.4.3. ROS formation in the mitochondria
Electrons can escape from the carriers and interact with oxygen to generate superoxide
(the progenitor of ROS) within the matrix. Under physiological condition, this process
is both inevitable and essential; ROS are important signaling molecules. Thus, the
concentration of electron carriers (in their reduced state i.e. NADH/FADHj) and the
rate of electrons released from the carriers are key determinants to the magnitude of
superoxide formation. AWm also exerts a considerable influence on superoxide
formation. In normal functioning mitochondria, an active ATP formation results in a
relatively low AlPm. This allows a steady flow of electrons across the mitochondrial
respiratory chain for constant NADH oxidation, thus minimizing the superoxide
formation (Figure 1.4.3.1).
Diminished forward electron movement, for instance, in the presence of damaged
mitochondrial respiratory chain, low ATP demand or with cytochrome c release during
apoptosis, reduces NADH oxidation. Consequently, NADH concentration (and
NADH/NAD+ ratio) would rise, favouring the electron leaks to form superoxide.
Under these circumstances, continuing NADH supply to Complex I could potentially
augment superoxide formation (Figure 1.4.3.2). Similarly, increased AWm enhances
mitochondrial superoxide formation. A significant rise in A for example, in the
presence of diminished ATP formation, can inhibit proton extrusion and forward
electron transfer. In these circumstances, the reverse movement of electrons (reverse
electron transport (RET)) from Coenzyme Q (ubiquinone) to complex I can occur. This
results in a reduction of NAD+ to NADH in Complex I, thus increasing the NADH






Figure 1.4.3.1. Superoxide formation in normal mitochondria.
In normal functioning mitochondria, an active ATP formation (pink arrow) results in a
relatively low A!Fm. Thus, a steady flow of electrons (red arrows) across the
mitochondrial respiratory chain continues to maintain constant NADH oxidation to
NAD+ (brown arrow). Superoxide formation is kept to a minimum with mitochondrial
antioxidant pathways countering any superfluous superoxide within the matrix. Q,











Figure 1.4.3.2. Mitochondrial superoxide formation in impaired respiration.
Impaired mitochondrial respiration results in decreased NADH oxidation to NAD+.
Similarly, any impediment to the release of electron from the carriers (red arrow) can
increase the concentration of NADH (and the NADH/NAD+ ratio) thus, enhancing
















Figure 1.4.3.3. Mitochondrial superoxide formation and reverse electron transfer.
Proton extrusion and forward electron transfer are inhibited when there is a significant
rise in A¥m. In these circumstances, the reverse movement of electrons from Coenzyme
Q (ubiquinone) to complex I, or reverse electron transport (RET), can occur. The
reversed movement of electrons promotes NAD+ reduction to NADH in Complex I.
The concentration of NADH increases dramatically, thus enhancing superoxide
formation. Q, Coenzyme Q (ubiquinone); Cyt c, cytochrome c.
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1.4.4. Potential mechanisms for increased ROS formation in NAFLD
Increased energy substrate is central to the development of dietary NAFLD. Increased
free fatty acid (FFA) flux, in tandem with hyperglycaemia that often characterized
insulin resistance, can augment tricarboxylic acid (TCA) cycle resulting in the
overproduction of electron donors NADH and FADH2. Consequently, electron
delivery to the respiratory chain is enhanced, paralleled by a rise in mitochondrial
respiration. Under this circumstance, active ATP formation, which lowers the A!Fm, is
crucial in minimizing the inherent ROS production. However, if the electron supply
exceeds the cellular ATP demand, NADH/NAD+ ratio and ROS will rise. Decreased
mitochondrial respiration and reduced ATP formation as often seen in steatohepatitis
can potentially sustain the ROS formation (59, 62, 66, 67).
1.4.5. Uncoupling and ROS formation in NAFLD
As discussed above, superoxide formation is highly sensitive to the changes in A!Fm;
increased AWm promotes superoxide formation and conversely, a reduction m AWm (for
example, during ATP formation) diminishes superoxide production (68). Decreased
can also occur when protons leak into the matrix independent of ATP synthase,
therefore, uncoupling the ATP synthesis from substrate oxidation. Under physiological
condition, basal proton leaks accounts for ~20—30% of the resting metabolic rate in
active tissues such as hepatocytes and is thought to represent a protective mechanism to
limit ROS production (69).
Proton leak is also inducible by uncoupling proteins (UCP). Superoxide, free fatty acids
and lipid peroxidation products such as HNE, have been shown to induce UCP (70-73).
UCP2 in particular, is strongly implicated in the pathophysiology of NAFLD. UCP2 has
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been shown to be significantly upregulated in obesity, insulin resistance and fatty
hepatocytes (74, 75). Although increased UCP2 attenuates superoxide formation, this
can occur at the expense of ATP formation and thus, can potentially induce necrosis
and increased susceptibility of hepatocytes to further injury (75, 76).
1.4.6. Oxidative stress and altered mitochondrial structure in NAFLD
Impaired mitochondrial function in NAFLD is often paralleled by alterations in
mitochondrial structure, the most striking of which, is the development of enlarged
mitochondria, collectively termed as megamitochondria (32, 77, 78). Their presence in
experimental steatosis was initially described 50 years ago (79). It is estimated that
megamitochondria occur in 5-15% of hepatocytes in steatohepatitis and are notably
absent in cirrhosis (80).
Megamitochondria is thought to reflect hepatocellular injury. In steatohepatitis,
megamitochondria are associated with oxidative stress, mitochondrial respiratory chain
impairment and diminished ATP formation (32). The ability of ROS to induce similar
alterations under experimental conditions suggests that these changes may represent
either a degenerative or an adaptive response to oxidative stress (81, 82).
Mitochondria exist as a reticular network maintained by a dynamic balance of fusion
and fission according to the cellular demand. A shift in balance towards fusion can
result in enlarged or elongated mitochondria. Conversely, increased fission promotes
smaller and fragmented mitochondria, as often seen during apoptosis (83). Interestingly,
elongated mitochondria formed by decreased fission leads to diminished ROS
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formation (84). This suggests that such alterations in mitochondrial structure may
represent an adaptive response to minimize ROS formation in the presence of oxidative
stress (82).
1.4.7. The relationship between ROS, mitochondrial function and insulin
resistance
There is increasing evidence both from in vivo dietary models of NAFLD and in vitro
hepatocyte lipid overload models, to suggest that hepatic lipid accumulation alters
insulin signaling (85-87). Insulin is the principal hormone in glucose homeostasis. It acts
by stimulating glucose influx and metabolism in muscle and adipocytes. In the liver,
insulin inhibits gluconeogenesis and promotes glycogen synthesis. Insulin also modifies
the expression and the activity of several enzymes including those involved in
lipogenesis. Its action is mediated through the insulin receptor, a transmembrane
glycoprotein with intrinsic protein tyrosine kinase activity. The binding of insulin to the
receptor triggers tyrosine phosphorylation which cascades through insulin receptor
substrates (IRS)/phosphatidylinositol 3-kinase (PI3K)/protein kinase B
(AKT)/forkhead box O transcription factor (FOXO) 1. Additionally, there is a parallel
pathway linking the insulin receptor to the lipogenic transcription factor SREBPlc
(Figure 1.4.7.1). Several studies have documented defects in molecules involved in the
IRS/PI3K/AKT/F0X01 signaling pathway in NAFLD (85, 88). The alterations in
insulin signaling are associated with increased endogenous glucose production (a marker
of hepatic insulin resistance) (89, 90). However, it is thought that the activation of






Figure 1.4.7.1. Insulin signaling.
The action of insulin is mediated by insulin receptor. The binding of insulin triggers
tyrosine phosphorylation of the insulin receptor, which cascades through
IRS/PI3K/AKT/F0X01 (red arrow). This signaling pathway is thought to be
selectively downregulated in hyperinsulinaemia. In contrast, a parallel pathway linking
the activation of insulin receptor to the transcriptional upregulation of lipogenic
transcription factor SREBPlc (brown arrow) remains fully functional and continues to
mediate lipogenesis. IR, insulin receptor; IRS, insulin receptor substrate; PI3K,
phosphatidylinositol 3-kinase; AKT, protein kinase B; FOXOl, forkhead box O
transcription factor 1; PIP, phosphatidylinositol phosphate; PIP2, phosphatidylinositol
4,5-bisphosphate; PIP3, phosphatidylinositol 3,4,5-trisphosphate; SREBP-lc, sterol
regulatory element binding protein-lc; ChREBP; carbohydrate responsive element
binding protein.
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Oxidative stress has been strongly implicated in the development of insulin resistance
(92). Increased expression of pro-oxidant CYP2E1 in steatohepatitis leads to the
development of insulin resistance (49). In a cellular model of steatosis, palmitate-
induced insulin resistance has been shown to be mediated by mitochondrial ROS (85).
Furthermore, activation of pro-inflammatory cytokines (e.g. TNF-a, IL-lp, and IL-6) by
ROS interferes with insulin signaling through activation of the kinases and transcription
factors such as JNK, NFkB, inhibitor of kappa B kinase-(3 (IKKP) (93).
However, the relationship between ROS and insulin resistance is undergoing
reexamination. For example, a recent study has shown that depending on the
concentrations, H202 can either enhance or attenuate insulin signaling (94). The finding
of enhanced PI3K/Akt signaling hence insulin sensitivity in mice with Gpxl deficiency
further supports this contention (95). Indeed, it has been proposed that ROS-mediated
insulin resistance is a cellular adaptive response to oxidative stress (96).
Similarly, it is unclear if triglyceride accumulation per se modulates insulin sensitivity.
Reduction in triglyceride accumulation does not necessarily improve insulin sensitivity
or prevent the progression to steatohepatitis. For example, inactivation of diacylglycerol
acyltransferase 2 (DGAT2), the enzyme that catalyses the final step of triglyceride
biosynthesis, dramatically reduces hepatic fat accumulation in a mouse model of
methionine choline deficient (MCD) but this is associated with exacerbation of
necroinflammatory activity and fibrotic response in the liver (97).
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Insulin TNF-a
Figure 1.4.7.2. The proposed mechanisms of insulin resistance.
ROS play an integral role in promoting insulin resistance in steatohepatitis. Potential
mechanism includes ROS activation of pro-inflammatory cytokines, which interferes
with insulin signaling through activation ofJNK and IKKp. A number of recent studies
have proposed that DAG activation of PKCe attenuates insulin signaling by promoting
serine (instead of tyrosine) phosphorylation of the insulin receptor. AP-1, activator
protein-1; DAG, diacylglycerol; IR, insulin receptor; IRS; insulin receptor substrate; IL,
interleukin; IL-1R, interleukin-1 receptor; IL-18R, interleukin-18 receptor; IKKP,
inhibitor of kappa B kinase-P; JNK, jun N-terminal kinase; NF-kB, nuclear factor-kb;




Our study sought to address several fundamental questions on hepatic mitochondrial
impairment in the presence of increased energy substrates.
1. Does steatosis exert deleterious effects on mitochondrialfunction in the absence o/ROS?
This is a critical question since a proportion of individuals with steatosis progress to
steatohepatitis. Evidence to support the role of mitochondrial dysfunction in NAFLD is
almost always associated with steatohepatitis and is inevitably characterized by increased
oxidative stress. The impact of cellular steatosis per se on mitochondrial function remains
uncertain. Yet, the reduction in intracellular triglyceride accumulation is often construed
as a marker of improvement in NAFLD.
2. What are the individual contributions from ROL, mitochondrial dyfunction and steatosis
towards the metabolic derangements associated with NAFUD?
Chief among the metabolic derangements in NAFLD is the development of insulin
resistance, which can lead to hyperglycaemia and hyperinsulinaemia. The contributions
of steatosis per se towards these metabolic derangements have not been determined.
Similarly, the relationship between mitochondrial dysfunction and the development of
hyperglycaemia remains unclear; does altered glucose metabolism precede, parallel, or
simply a consequence of impaired mitochondrial function?
3. What are the effects of the intracellular antioxidant N-acetylcysteine on hepatic mitochondrial
function and metabolic alterations associated with cellular steatosis'?
N-acetylcysteine, an antioxidant known to reduce cellular ROS, has been shown to
enhance mitochondrial function in adipocytes, cardiac and skeletal muscle (98-100).
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However, the effects of NAC on hepatic mitochondrial function and metabolic
alterations associated with human steatohepatitis are yet to be established (32).
4. Does medium chain fatty acid invoke different metabolic responses in hepatotytes when
compared with long chainfatty acid?
The ability of medium chain free fatty acids (MCFA) such as octanoate, to diffuse into
the mitochondria independent of carnitine palmitoyl transferase (CPT) allows a more
efficient (3-oxidation than long chain fatty acids (LCFA) (101). Indeed, increased basal
lipolysis with octanoate in adipocytes has prompted interest in the use of MCFA to
induce weight loss (102, 103). The effect of MCFA including octanoate on hepatic
mitochondrial function and ROS formation particularly in a milieu that is already
burdened by enhanced respiration have not been previously examined.
1.6. In vitro model
Dissecting the pathophysiology of NAFLD is often hampered by the relative
inaccessibility of the liver. Although liver biopsy remains as the gold standard in
diagnosing steatohepatitis clinically, it is invasive and prone to sampling error. Thus,
repeat biopsies to demonstrate the continuum of the pathophysiology involved in
NAFLD is not feasible.
Many of the animal models of NAFLD have provided vital insights into the
pathophysiology involved but are yet to recapitulate the entire phenotype as
encountered in clinical practice. More important, many differ from the metabolic
aspects of the human disease despite the similarities in gross histological appearance
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(104). Furthermore, dissecting the contribution of steatosis, ROS and mitochondrial
function in the liver is difficult to achieve in vivo owing to the confounding factors such
as peripheral insulin resistance and adipocytokines. By comparison, in vitro studies
provide a controlled environment, independent of the influence exerted by
adipocytokines and peripheral hyperinsulinaemia thus focusing on events that occur
specifically in the liver.
The most important prerequisite of an in vitro model of NAFLD is cellular steatosis.
Most of the existing in vitro models are based on lipid loading where hepatocytes are
incubated with optimal concentrations of free fatty acids to induce steatosis. Free fatty
acid such as oleate, alone or in combination with palmitate are most commonly used.
This is largely based on studies suggesting that triglyceride accumulation in NAFLD is
largely driven by an increase in palmitate and oleate (105, 106).
However, achieving similar triglyceride composition does not necessarily recapitulate
human NAFLD. For example, oleate promotes triglyceride accumulation but without
excessive ROS formation or insulin resistance (107). Palmitate is poorly incorporated
into triglyceride and its use is limited by its propensity to induce apoptosis (108). More
important, both are long chain free fatty acids rendering them relatively unsuitable for
examining the impact of accelerated mitochondrial superoxide formation. The
underlying reason is that their entry into the mitochondria has to be regulated by
carnitine palmitoyl transferase (CPT), a rate-limiting en2yme for P-oxidation. Thus, the
production of mitochondrial ROS with long chain fatty acids can be unpredictable.
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1.7. LPON as an in vitro model of cellular steatosis
One of the main objectives of the present study was to examine in vitro the relationship
between energy substrates, mitochondrial reactive oxygen species (ROS) formation and
mitochondrial function in the presence of hepatic steatosis. In dietary-induced NAFLD,
the sequence of events is almost always instigated by increased energy substrate, which
promotes hepatic steatosis as well as enhances cell respiration and hence ROS
formation. In order to recapitulate this sequence of events, we designed an in vitro model
using energy substrates that can enhance respiration. The prerequisites of the substrates
chosen are their ability to induce adequate steatosis in addition to their capacity in
promoting tricarboxylic acid cycle (TCA) to generate NADH for mitochondrial
respiratory chain. Being a medium chain free fatty acid (MCFA), octanoate, enters
mitochondria independent of carnitine palmitoyl transferase (CPT) leading to an
efficient (3-oxidation. Acetyl-coA generated from complete and exclusive (3-oxidation
can be incorporated into triglyceride through de novo lipogenesis. Indeed, the acyl chains
of triglyceride formed by octanoate through de novo lipogenesis are palmitate and
palmitoleate (101).
Acetyl-coA can also enter the TCA cycle culminating in the formation of reducing
equivalents (NADH/FADH2) destined for mitochondrial respiratory chain. Thus, we
chose octanoate due its ability to induce adequate steatosis in addition to its immediate
availability as an energy substrate to the TCA cycle. In stark contrast to octanoate, the
entry of long chain fatty acid (LCFA), oleate, into the mitochondria has to be regulated
by CPT, a rate-limiting enzyme for (3-oxidation. Direct esterification of oleate allows
significant triglyceride accumulation but without excessive ROS species formation.
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We used C3A cells, a clonal derivative of human hepatoblastoma HepG2, treated with
either oleate or octanoate to induce triglyceride accumulation. These FFA were chosen
due to their contrasting effects on (3-oxidation and ROS production. The rate of
mitochondrial respiration was further manipulated by adding the end products of
glycolysis, lactate (L) and pyruvate (P) to octanoate (O). The reasoning was that these
energy substrates would synergistically enhance mitochondrial respiration and promote
significant intracellular lipid accumulation through de novo lipogenesis. To augment the
endogenous ROS synthesis further, we added ammonia to the LPO combination with
the hypothesis that the metabolism of ammonia by the urea cycle or the glutamine
pathways (in the presence of suboptimal urea cycle, for example, in progressive hepatic
dysfunction as well as in HepG2/C3A cells) would promote NADH formation and
further enhance mitochondrial respiration (109, 110).
The focus was then to observe the events that occurred as consequences of enhanced
TCA activity similar to what potentially may occur with nutrient excess.
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Figure 1.7. In vitro model of cellular steatosis using LPON.
LPON were chosen for their swift ability to form acetyl-coA for TCA cycle. Acetyl-coA
is formed by the recurring sequence of (3-oxidation and from pyruvate by pyruvate
dehydrogenase. Acetyl-coA enters the TCA cycle with resultant NADH formation for
mitochondrial respiratory chain. Additionally, it can contribute towards de novo
lipogenesis. We hypothesized that the combination of the substrates would increase the
turnover of the TCA cycle resulting in enhanced NADH formation. Consequently,
mitochondrial respiration is augmented and ROS formation is increased. MRC,
mitochondrial respiratory chain; TCA, tricarboxylic acid cycle.
49
1.8. C3A cells
C3A cells, a derivative of human hepatoblastoma cell line HepG2, is selected for its
enhanced hepatic phenotype (111, 112). C3A cells retain most of the primary hepatocyte
functions including albumin synthesis, alpha-fetoprotein formation, GSH synthesis and
to a certain extent, cytochrome P450 for detoxification (113, 114). Indeed, these
characteristics support their use in bioartificial liver devices (111). When cultured in
three-dimensional spheroids, C3A cells demonstrate typical morphology of the primary
hepatocyte i.e. tight junctions, polar cells, the presence of bile canaliculi and enhanced
cytochrome P450 expression (115). Importantly, C3A cells are able to accumulate
triglyceride when exposed to free fatty acids and have been previously used as an
experimental model of cellular steatosis (116).
Although primary hepatocytes have superior metabolic and synthetic function than C3A
cells, these characteristics diminish within 72 hours. By comparison, gluconeogenesis,
galactose elimination and (3-oxidation are sustained in C3A cells even after 10 days of




GENERAL MATERIALS AND METHODS
2.1. Material
2.1.1. Cell culture
The C3A cell line (CRL-10741) was obtained from American Type Culture Collection,
Manassas, VA, USA. Minimal essential medium Eagle (MEME), Hank's balanced salt
saline (HBSS), phosphate-buffered saline (PBS), sodium pyruvate,
penicillin/streptomycin solution, trypsin, fetal bovine serum (FBS) were purchased from
Sigma, Poole, UK. 75cm2, 25cm2 flasks and 6-well plates were resourced from Corning,
NY, USA.
2.1.2. Other chemicals
Bovine serum albumin powder (BSA), insulin, sodium azide, 4% paraformaldehyde, 2,4-
dinitrophenol (DNP), oligomycin, N-acetylcysteine, dimethyl sulphoxide (DMSO),
NAD+, glycine, hydrate hydrazine, (3-hydroxybutyrate dehydrogenase, NADH, and
metformin (Sigma Aldrich, Poole, UK); ProLong® gold antifade reagent (Invitrogen,
NY, USA); lactate dehydrogenase (LDH) and triglyceride assays (Alpha Laboratories,




2.2.1. Cell culture and maintenance
C3A cells were cultured in 75 cm2 tissue culture flasks in minimal essential medium
Eagle (MEME) with 10% fetal calf serum (FCS) and antibiotics (lOOIU/ml penicillin,
lOOmg/ml streptomycin) at 37°C and 5% COz until 70% confluent. The medium was
changed every 48 hour after the initial plating. Cells were passaged every 7-10 days.
2.2.2. Cell culture preparation for experimentation
When C3A cells reached 70% confluence, culture medium was aspirated and the
attached cells were washed twice with HBSS. Cells were then incubated for 10 minutes
at 37°C with 5ml trypsin/EDTA. After 10 minutes, 5ml MEME with FCS was added to
each flask and the contents were centrifuged (600 rpm for 2 minutes). The supernatant
was discarded, resuspended in MEME with FCS and cells were aliquoted to
experimental plates.
2.2.3. Treatment with energy substrates
MEME with FBS in the experimental plates was supplemented with combinations of
octanoate (O) (2mM) or oleic acid (Ol) (0.25mM) (complexed with bovine serum
albumin (BSA)), lactate (L) (lOmM), pyruvate (P) (ImM), with or without ammonia (N)
(4mM). Cells were cultured in the supplemented media for 72 hours (unless specified)
prior to experimentation. Unless stated otherwise, cells were cultured in triplicates.
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2.2.4. Supernatant and cell collection
Supernatant from each treatment group was aspirated, aliquoted into 750fxl tubes and
kept on ice for immediate analyses. Cell monolayer was rinsed twice with 2ml of PBS
(with added calcium chloride and magnesium chloride). Further PBS (500pl) was added
to each well and cells were then gently harvested mechanically using a soft spatula. The
pellets were kept frozen at -80°C.
2.2.5. Total protein assay
Cell pellets were thawed, lysed by sonication (three pulses of 10 seconds using a
Soniprep 150 Sonicator, Wolf Laboratories Ltd., York, UK). Protein measurements
were determined using the standard BCA Protein Assay. Briefly, BCA working reagent
was prepared as specified by the manufacturer. An aliquot of lOpl from the sample were
placed in 96-well plate. The reagent (20[tl) was added to each sample. After a 30 minute
incubation at 37°C, readings were made on a spectrophotometer set to an absorbance of
562nm. Protein concentrations were obtained from standard curves prepared as
specified by the manufacturer.
2.2.6. Cell viability
Cell viability was assessed as the percentage retention of lactate dehydrogenase (LDH)
in the cell monolayer as originally described by Gay et al. (117). Briefly, intracellular and
extracellular LDH activities of the cell lysates and culture medium respectively, were
determined by the rate of NAD+ reduction to NADH. This reaction corresponds to a
decrease in absorbance at 340nm, which in turn, is direcdy proportional to LDH
activity. LDH was detected using a commercial LDH assay (Alpha Laboratories,
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Hampshire, UK) modified for use on the Cobas-Fara centrifugal analyser (Roche
Diagnostics Ltd., Welwyn Garden City, UK). The results were expressed as % LDH
activity retained, calculated from: intracellular LDH activity/(extracellular LDH activity
+ intracellular LDH activity) x 100.
2.3. Statistical analyses
Statistical analyses were performed using GraphPad Prism® (GraphPad Software, CA,
USA). Results are expressed as mean ± standard error of the mean (SEM) except for
data obtained from metabolomics profiling, which are presented as mean ± standard
deviation (SD). Unless stated otherwise, differences between groups were compared
with one-way ANOYA with Newman-Keuls multiple comparison analysis to determine




INDUCTION OF CELLULAR STEATOSIS IN VITRO
3.1. Introduction
Triglyceride accumulation is the hallmark of NAFLD. Triacylglycerol or triglyceride is a
major neutral lipid, which comprises three fatty acids attached by ester bonds to a
glycerol backbone. Stored within the lipid droplets in cytoplasm, triglyceride is an
efficient fatty acid storage molecule, not only crucial for energy homeostasis but is also
vital for maintaining cell membrane composition and lipoprotein secretion. Lipid
droplets are highly dynamic, which in response to the appropriate signals, can be
esterified, hydrolyzed or reesterified to meet cellular demand (118). Importantiy,
triglyceride is fundamental in protecting cells against the deleterious effects of free fatty
acids (108).
The association between triglyceride accumulation and deranged metabolic states is well
established. However, the relationship is complex. In essence, it is unclear whether
triglyceride accumulation is the cause or simply a marker of the deranged metabolic
milieu.
The presence of intracellular triglyceride accumulation is a cardinal feature of any in vitro
model aiming to dissect the pathogenesis of NAFLD. We chose a long chain fatty acid,
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oleate, or a medium chain fatty acid, octanoate, to induce triglyceride accumulation in
C3A cells. Additionally, lactate and pyruvate were added to octanoate to synergistically
promote significant intracellular lipid accumulation through de novo lipogenesis.
The aims of this chapter are:
1. To confirm that the energy substrates would induce intracellular lipid
accumulation in vitro.
2. To quantify and examine the pattern of triglyceride accumulation induced by the
specified combination of energy substrates.
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3.2. Methods
3.2.1. Oil red O staining
Cells were plated on chamber slides and treated for 72 hours. Treated cells were fixed
with 10% formaldehyde at room temperature for 10 minutes and washed in 60%
isopropanol for 30 seconds. Oil red O staining was conducted by Mr. Robert Morris,
Queens Medical Research Institute, using method previously described by Green and
Kehinde (119). Briefly, Oil red O (0.2g) was dissolved in 200ml of isopropanol. The
solution was warmed to 56°C for at least one hour and then cooled at room
temperature. Working solution was prepared immediately before use by adding 4 parts
of distilled water to 6 parts stock solution. This solution was then vortexed and left for
10 minutes before filtering it through a fine filter paper (No. 42 Whatman). Slides were
stained with Oil red O for 10 minutes and washed in 60% isopropanol for 5 seconds.
Mayer's haematoxylin solution (1 ml) was added. After 30 seconds, slides were rinsed
with distilled water, counterstained with sodium phosphate for 5 minutes and air-dried
before being mounted using a water-based preservative. Slides were viewed using
Olympus BH-2 light microscope (Olympus America Inc., NY, USA), and digital images
were captured using attached camera (Leica, Solms, Germany) at the magnification of
10, 20 and 40x.
3.2.2. BODIPY 493/503 staining
BODIPY® 493/503 (4,4-difluoro-3a, 4a- diaza-s-indacene) (Invitrogen, NY, USA) is a
non-polar, lipophilic fluorescent dye that stains neutral lipid intense green. Cells were
treated on chamber slides for 72 hours and fixed with 4% paraformaldehyde for 30
minutes before staining with 200ul of BODIPY 493/503 for 10 minutes. Diamidino
57
phenylindole (DAPI) was used to stain the nuclei where appropriate. Cells were
mounted in coverslips using ProLong® gold antifade reagent and were left for 24 hours
at 4°C before viewed using confocal laser microscope (LSM510; Carl Zeiss
Microimaging, Inc., Cambridge, UK). Fluorescent intensity from at least 50 cells per
image was analyzed using ImageJ software (National Institutes of Health, Bethesda,
MD, USA). To determine the number of lipid droplets, the stack of 3D BODIPY
confocal images were analysed using Volocity 3D image analysis software (Perkin
Elmer, Waltham, MA, USA).
3.2.3. Triglyceride concentration
Oil red O and BODIPY 493/503 stainings are useful to demonstrate neutral lipids
within cells but they are not without pitfalls. Variations in the dye penetration can affect
the intensity of the staining and sampling bias during image acquisition can often occur.
These factors render them relatively inaccurate for quantitative analyses. Thus, if
possible, they should be complemented with direct measurements of cellular triglyceride
levels.
To determine triglyceride concentrations, cells were treated with the specified
combination of energy substrates in 6-well plates (in triplicates) for 24, 72 and 120
hours. Cell pellets were prepared as described in section 2.2.4. Cells were then thawed
and lysed by sonication (three pulses of 10 seconds) (Soniprep 150 Sonicator, Wolf
Laboratories Ltd., York, UK).
Intracellular triglyceride concentrations were measured using a commercial kit adapted
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for the Cobas-Fara centrifugal analyzer (Roche Diagnostics Ltd., Welwyn Garden City,
UK). The assay was based on the following reactions:
• Triglycerides hydrolysis by lipoprotein lipase results in the formation of glycerol
and fatty acids.
• Glycerol kinase phosphorylates glycerol to form glycerol 3-phosphate (in the
presence of ATP).
• Glycerol 3-phosphate is subsequently oxidised by glycerol-3-phosphate oxidase
to produce dihydroxyacetone phosphate and hydrogen peroxide.
• The enzyme peroxidase catalyses the reactions between hydrogen peroxide, 4-
aminoantipyrine and 3,5-dichloro-2-hydroxybenzene sulfonate resulting in the
formation of a red compound, the intensity of which is proportional to the
concentration of triglyceride.
Cell pellets were microcentrifuged at 11,000g for 10 minutes prior to the triglyceride
measurement. Precinorm® U was used for quality control. The reagent (300pi) and the
sample (3pl) were incubated at 37°C for 5 minutes before spectrophotometer analysis
(500nm). Triglyceride concentration is normalized to the total protein and expressed as
pg per gram of total protein.
3.2.4. Electron microscopy
Cells were centrifuged to form pellets in the fixative (3% glutaraldehyde in 0.1M sodium
cacodylate buffer, pH 7.3) then washed in three 10-minute changes of 0.1M sodium
cacodylate. Specimens were then post-fixed in 1% osmium tetroxide in 0.1M sodium
cacodylate for 45 minutes, and washed in three 10-minute changes of 0.1M sodium
cacodylate buffer. Samples were dehydrated in 50%, 70%, 90% and 100% normal grade
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acetones for 10 minutes each, then for a further two 10-minute changes in analar
acetone. Samples were embedded in Araldite resin. Sections, 1 pm thick, were cut on a
Reichert OMU4 ultramicrotome (Leica Microsystems Ltd., Milton Keynes, UK), stained
with toluidine Blue and viewed in a light microscope. Ultrathin sections of 60nm were
cut from selected areas, stained in uranyl acetate and lead citrate before viewed in
Phillips CM120 Transmission electron microscope (FEI UK Ltd., Cambridge, UK).
Images were taken using Gatan Orius CCD camera (Gatan UK, Oxford, UK).
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3.3. Results
3.3.1. Lipid droplets are visible under electron microscopy
First, we confirmed the presence of lipid droplets in cells treated for 72 hours using the
electron microscopy. Figure 3.3.1.1 (Panel A-D) are representative images from electron
microscopy demonstrating the presence of intracellular lipid vacuoles in all treatment
groups. Lipid droplets were present in the cytoplasm juxtaposed among the
mitochondria (Figure 3.3.1.1).
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Figure 3.3.1.1. Lipid droplets in treated cells viewed under electron microscopy.
A, Untreated; B, Octanoate; C, LPON and D, Oleate treated cells. Cells were treated for
72 hours and centrifuged to form pellets described in section 3.2.4 for electron
microscopy, d, droplets; m, mitochondria, n, nucleus (scale bar represents 1 pm,
magnification x4800).
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3.3.2. Oil red O and BODIPY 493/503 confirm the presence of triglyceride
Oil red O staining (Figure 3.3.2.1) and BODIPY 493/503 staining (Figure 3.3.2.2 and
3.3.2.3) confirmed the presence of triglyceride. As demonstrated in Figure 3.3.2.1, lipid
droplets were stained red with Oil red O. Similarly, Figure 3.3.2.2 Panel A and B are
representative images of treated C3A cells stained with BODIPY 493/503. BODIPY
493/503 stained lipid droplets fluorescent green whilst DAPI blue fluorescent staining
highlighted the nuclei. Panel C demonstrates the number of lipid droplets accumulated
after 24 hours of treatment with specified energy substrates.
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Figure 3.3.2.1. Oil red O staining in treated C3A cells.
Cells were grown and treated in two chamber slides. After a 72-hour treatment, cells
were fixed and Oil red O staining was performed as described in section 3.2.1. The area
with triglyceride accumulation was stained bright red. Images were viewed under light













Figure 3.3.2.2. BODIPY 493/503 staining in treated C3A ceils.
Cells were treated in two-chamber slides for 24 hours before BODIPY 493/503 and
DAPI staining (described in section 3.2.2). A, LPON; B, Oleate; C, The number of
lipid droplets accumulated after a 24-hour treatment with specified energy substrates
quantified by 3D image processing software, Volocity.
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Figure 3.3.2.3. BODIPY 493/503 staining in treated C3A cells.
Cells were treated in two-chamber slides for 72 hours before BODIPY 493/503 staining
(described in section 3.2.2). A, Untreated; B, LPON; C, Octanoate; D, Oleate; E, Area
with intense fluorescence from BODIPY staining quantified using ImageJ. Data are
presented as mean ± SEM; P<0.0001; *** P<0.001, **P<0.01.
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3.3.3. Triglyceride concentration in treated cells
Next, we quantified and examined the pattern of intracellular lipid accumulation. Cells
were treated with specified combinations of energy substrates over 24, 72 and 120
hours. Intracellular triglyceride concentrations were measured at each time point. With
the exception of ammonia, all groups showed significantly higher lipid accumulation
than the untreated cells at 72 and 120 hours (Figure 3.3.3). However, the pattern of
accumulation differed over time, notably, the contrasting pattern of triglyceride
accumulation between oleate and octanoate. Oleate induced higher triglyceride
concentrations in the first 24 hours but this subsequently plateaued. In contrast,
triglyceride concentration with octanoate increased with time potentially reflecting de
novo lipogenesis from acetyl-coA rather than direct esterification. The synergistic effect
of lactate, pyruvate and octanoate (LPO) resulted in higher triglyceride accumulation
than that seen with either LP (P<0.001) or octanoate alone (P<0.001). Triglyceride
concentrations with LPON after 72 hours were 40% lower than seen with LPO
(P<0.001) but were similar to that accrued with oleate.
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Figure 3.3.3. Triglyceride concentrations in treated C3A cells.
Triglyceride concentrations were measured after a 24, 72 or 120-hour treatment.
P<0.0001 for interaction between treatment and duration of treatment (determined
using two-way ANOVA). ***P<0.001 and *P<0.05 when compared to the untreated cells
of the same treatment duration; n—3 in triplicates. Data are presented as mean ± SEM.
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3.4. Discussion and conclusion
This chapter is focused on confirming the presence of intracellular triglyceride
accumulation, an important prerequisite for an in vitro model designed to dissect the
pathophysiology of NAFLD.
The main findings from this chapter are:
1. The combination of energy substrates, LPON, induced significant triglyceride
accumulation in vitro.
2. The addition of lactate and pyruvate synergized with octanoate to promote
significant triglyceride accumulation.
These findings highlight two main observations. First, the pattern of lipid accumulation
differs between oleate and octanoate. Oleate led to a dramatic rise in triglyceride
accumulation within 24 hours, but plateaued thereafter consistent with direct
esterification that parallels its concentration (120). In contrast, the incorporation of
octanoate into triglyceride followed a steady time-dependent course, which reflects de
novo lipogenesis from the acetyl-coA. This disparity stems from their differences in (T
oxidation. The recurring sequence of efficient (Toxidation with octanoate accelerates the
formation of acetyl-coA, which serves as the foundation for fatty acid synthesis (101)
(Figure 3.4.1).
Acetyl-coA is die crossroad between glucose and lipid metabolism. The conversion of
pyruvate, the end product of glycolysis, into acetyl-coA is a crucial step in partitioning
69
excess carbohydrate into fat for storage. Indeed, the synergistic effect of lactate,
pyruvate and octanoate in promoting a time-dependent rise in triglyceride most likely
through de novo lipogenesis highlights the importance of carbohydrate, for instance, in
hyperglycaemic conditions, in the formation of hepatic steatosis. Interestingly, we have
demonstrated that triglyceride concentration decreased with ammonia. The mechanism
involved is yet to be delineated. In astrocytes, ammonia has been demonstrated to
accrue diacylglycerol, instead of triacylglycerol (121).
Second, the co-localization between lipid droplets and mitochondria supports the
contention that dynamic metabolic and physical interactions exist between these
organelles. This has been previously observed in adipocytes and skeletal muscle, and is
thought to promote efficient FFA delivery for ATP formation.
In conclusion, LPON induces a significant triglyceride accumulation fundamental for an
in vitro model of cellular steatosis.
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Figure 3.4.1. The patterns of lipid accumulation in cells treated with oleate or
octanoate.
Both oleate and octanoate can lead to a significant triglyceride accumulation. However,
triglyceride accumulation with octanoate follows a steady time-dependent course
through de novo lipogenesis whilst oleate is direcdy esterified. The differences reflect the
variation in |3-oxidation. Octanoate has an efficient (3-oxidation resulting in acetyl-coA
formation, which can be diverted towards the de novo lipogenesis. In contrast, the entry
of oleate into the mitochondria hence its |3-oxidation is regulated by CPT1. MRC,












Figure 3.4.2. Lactate, pyruvate and octanoate synergize to promote de novo
lipogenesis.
The synergistic effect of pyruvate and octanoate leads to enhanced acetyl-coA
formation. Acetyl-coA can be diverted towards the de novo lipogenesis. The close
proximity between mitochondria and lipid droplets allows FFA released from
triglyceride hydrolysis to enter mitochondria for (3-oxidation. FFA, free fatty acids;




LPON ENHANCES ACUTE RESPIRATION AND REACTIVE
OXYGEN SPECIES FORMATION
4.1. Introduction
Central to the development of dietary-induced NAFLD is enhanced energy substrate
availability to the hepatocytes. This is often compounded by increased free fatty acids in
tandem with hyperglycemia that characterizes insulin resistance. The surge in energy
substrates can culminate in the overproduction of electron donors NADH/FADH2,
thus enhancing mitochondrial respiration and the formation of its byproduct,
superoxide.
Our aim was to recapitulate this sequence of events in vitro using C3A cells treated with
a combination of energy substrates, lactate, pyruvate, octanoate and ammonia (LPON).
We postulated that LPON could swiftly maximize the TCA cycle turnover and enhance
the formation of reducing equivalents (NADH/FADH^ with resultant rise in
mitochondrial respiration and superoxide formation.
Flaving shown that LPON induced triglyceride accumulation, in this chapter, we
examine the impact of LPON on acute mitochondrial respiration and ROS formation.
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The aims of this chapter are:
1. To determine whether the combination of energy substrates lactate, pyruvate,
octanoate and ammonia would acutely increase cell respiration.
2. To examine whether the potential rise in respiration with LPON would enhance
superoxide formation.




C3A cells were grown in 25cm2 flasks until 70% confluent. Naive cells were rinsed with
HBSS (10ml) before trypsinization (trypsin (5ml) with EDTA) for 5 minutes.
Trypsinized cells were centrifuged for 2 minutes and resuspended in MEME (with FBS)
(2ml). Cells were subsequently counted to obtain 0.5xl06 cells in single suspension,
which were then added to each well of the BD™ Oxygen Biosensor 96-well plate (BD
Biosciences, CA, USA) containing the specified media; oleate or octanoate with/without
the combination of lactate and pyruvate with/without ammonia. The BD™ Oxygen
Biosensor System is a 96-well plate-based sensor containing a ruthenium based-dye
incorporated into the silicon rubber matrix. The matrix and the dye are impermeable to
liquid but are freely permeable to oxygen. The fluorescent change with oxygen
consumed during respiration allows the determination of respiration rate. The
fluorescent plates were read in CytoFluor Reader Series 4000 (Applied Biosystems, NY,
USA) for 40 cycles, for 40 minutes. The respiration rates were measured from the linear
portion of the slope of fluorescence rise. Data are presented as fold of change from the
untreated cells.
4.2.2. Mitochondrial superoxide formation
Mitochondrial superoxide is generated within the mitochondria from the reduction of
02 by an electron during oxidative phosphorylation. Mitochondrial superoxide
production was measured using the live-cell permeable fluorescent probe MitoSOX™
(Invitrogen, NY, USA). Once in the mitochondria, MitoSOX™ is oxidized by
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superoxide and exhibits red fluorescence. Briefly, MitoSOX™ stock solution was
prepared according to protocol specified by the manufacturer. For fluorescent
microscopy, naive C3A cells grown in two-chamber slides were incubated with
MitoSOX™ for 60 minutes at 37°C. The supernatant was then removed and cells were
rinsed, before the addition of 500pl of HBSS with or without specified combination of
the energy substrates into each chamber. The slides were kept at 37°C and viewed under
fluorescent microscopy. Images of phase contrast and fluorescent field were obtained
using fluorescent microscopy (LSM510; Carl Zeiss Microimaging, Inc., Cambridge,
UK). These images were then merged using image editor software, Photoshop CS4,
(Adobe Systems Incorporated, San Jose, CA, USA). Fluorescence intensity from each
image was analysed using ImageJ (National Institute of Health, Bethesda, MD, USA).
4.2.3. Cell viability
Cell viability was assessed as the percentage retention of lactate dehydrogenase (LDH)
as previously described in the section 2.1.6.
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4.3. Results
4.3.1. Acute LPON treatment enhances respiration in C3A cells
We postulated that the combination of lactate, pyruvate, and ammonia would act
synergistically with octanoate to enhance mitochondrial respiration thus increasing
superoxide formation in a mechanism akin to that proposed in human NAFLD. To test
this hypothesis, treatment media were added to naive C3A cells before the
measurements of cell respiration. As shown in Figure 4.3.1, LPO resulted in a 2.5-fold




Figure 4.3.1. Acute respiration in C3A cells exposed to the specified energy
substrates.
Naive C3A cells in single suspension were used for each well of the BD™ Biosensor
fluorescent plate containing one of the following media: HBSS with oleate (0.25mM) or
specified combinations of lactate (L) (lOmM), pyruvate (P) (ImM), octanoate (O)
(2mM) and ammonia (N) (4mM). Cell respiration was calculated from the slope of the
linear section of the curve representing the fluorescence rise. Data are presented as
mean ± SEM; P=0.0008; "P<0.01, *P<0.05.
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4.3.2. Mitochondrial superoxide formation
4.3.2.1. MitoSOX™ as an indicator of superoxide formation
Next, we investigated whether the acute rise in respiration with LPON is paralleled by
enhanced ROS formation. The formation of mitochondrial superoxide, the progenitor
of ROS, is examined using MitoSOX™ as described in section 4.2.2. MitoSOX™ emits
red fluorescence when oxidized by superoxide. Panel A of Figure 4.3.2.1 is a
representative image ofmitochondrial superoxide fluoresced bright red in the naive cells
after a 60-minute labeling with MitoSOX™. Panel B shows the corresponding phase
contrast image (Panel C). These images were merged to juxtapose superoxide with the
cells (Panel D).
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Figure 4.3.2.1. Mitochondrial superoxide fluoresces red with MitoSOX1M
staining.
Naive C3A cells grown in two-chamber slides were incubated with MitoSOXIM for 60
minutes at 37°C. The slides were viewed under fluorescent microscopy. A,
Representative image of naive cells incubated with MitoSOX1' emitting bright red
fluorescence indicating the presence of superoxide; B, Phase contrast image; C,
Fluorescent image; D, Phase contrast and fluorescent images merged (magnification
x40).
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4.3.2.2. Enhanced mitochondrial superoxide formation with LPON
To determine the effect of LPON on ROS formation, naive C3A cells grown in two-
chamber slides were incubated with MitoSOX™ for either 45 or 60 minutes at 37°C.
The supernatant was then removed and cells were rinsed, before the addition of 500ul
of HBSS with or without LPON into each chamber. Additionally, HBSS with DNP
(250uM) (negative control) or HBSS with oligomycin (5 ftg/ml) (positive control) were
added to separate group of cells.
Oligomycin is an ATP synthase inhibitor and acts by blocking the passage of protons
through the mitochondrial ATP synthase. This results in an increase in mitochondrial
membrane potential (A1/^). As discussed in section 1.4.3, proton extrusion and forward
electron transfer are inhibited with a significant rise in A!Fm. Under these circumstances,
NADH oxidation is impaired leading to a rise in NADH concentration thus promoting
electron leaks and superoxide formation (122). Furthermore, reverse electron transport
(RET) can occur, which can potentially enhance superoxide formation.
Conversely, a reduction in A*Fm decreases superoxide production (123). Uncoupler such
as 2,4-dinitrophenol (DNP) can render the inner membrane permeable to protons,
thereby lowering the AWm. Even at low concentrations, these uncouplers have been
shown to considerably reduce the rate ofmitochondrial superoxide production (123).
Figure 4.3.2.2 and 4.3.2.3 are representative images of mitochondrial superoxide
formation after a 45- and 60-minute labeling with MitoSOX™ respectively. The addition
of LPON (Panel B) to the naive C3A cells visibly resulted in higher mitochondrial
superoxide formation than the untreated cells (Panel A). The quantification of the
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fluorescent area using ImageJ confirmed these findings (Panel E). The rise in
mitochondrial superoxide formation with LPON was comparable to that seen with
oligomycin. Indeed, LPON resulted in a higher superoxide formation than oligomycin
when labeled with MitoSOX™ for 60 minutes. In contrast, mitochondrial superoxide
formation with DNP was similar to the untreated cells and was considerably lower than
that seen with LPON or oligomycin.
4.3.3. Cell viability is unaltered with LPON
We determined cell viability by measuring the LDH retention in cells that have been
treated with LPON for 72 hours as described in section 2.1.6. LPON did not alter cell
viability (LPON 97.9 ± 0.33, oleate 98.2 ± 0.32, untreated 98.3 ± 0.39 % LDH activity
retained; P=0.63).
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Figure 4.3.2.2. Mitochondrial superoxide formation after a 45-minute labeling
with MitoSOX™.
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A, Untreated; B, LPON; C, Oligomycin; D, DNP; E, Area with intense fluorescence
quantified using ImageJ. Naive C3A cells grown in two-chamber slides. Confluent cells
were then incubated with MitoSOX™ for 45 minutes at 37°C. Cells were rinsed before
being treated with 500pl of HBSS with or without LPON into each chamber.
Additionally, HBSS with DNP (250pM) or HBSS with oligomycin (5jJ.g/ml) were added
to separate group of cells. Oligomycin hyperpolarizes mitochondria thus increasing the
leakage of electrons enhancing superoxide formation. In contrast, 2,4-dinitrophenol
(DNP) lowers the A!Pm, hence diminishing the rate of superoxide production by
mitochondria. Panel A-D are fluorescent images viewed under fluorescent microscopy
and E, fluorescent area quantified using ImageJ. Data are presented as mean ± SEM;
P<0.0001; "*P<0.001,~P<0.01.
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Figure 4.3.2.3. Mitochondrial superoxide formation after a 60-minute labeling
with MitoSOX™.
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A, Untreated; B, LPON; C, Oligomycin; D, DNP; E, Area with intense fluorescence
quantified using ImageJ. Naive C3A cells grown in two-chamber slides. Confluent cells
were then incubated with MitoSOX™ for 60 minutes at 37°C as described previously.
Cells were rinsed before being treated with 500pl of HBSS with or without LPON into
each chamber. Additionally, HBSS with DNP (250pM) or HBSS with oligomycin
(5pg/ml) were added to separate group of cells. Panel A-D are fluorescent images
viewed under fluorescent microscopy and E, Fluorescent area quantified using ImageJ.
Data are presented as mean ± SEM; P<0.0001; ***P<0.001, **P<0.01.
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4.4. Discussion and conclusion
Our aim was to design an in vitro model of cellular steatosis that would recapitulate the
sequence of events proposed to occur in dietary-induced NAFLD. We postulated that
the combination of energy substrates, LPON, would fulfill the three prerequisites for
such an in vitro model; adequate cellular steatosis, exaggerated cell respiration and
enhanced superoxide formation. We have confirmed previously that LPON induces
significant cellular steatosis. This chapter is focused on whether LPON would augment
respiration and increase superoxide formation.
The main findings in this chapter are:
1. LPON acutely increased cell respiration in naive C3A cells.
2. The rise in acute respiration with LPON was paralleled by an increase in
superoxide formation.
3. Despite enhanced superoxide formation, prolonged treatment with LPON did
not affect cell viability.
These findings highlight two important points. First, LPON fulfills the three
prerequisites of an in vitro cellular steatosis model aiming to recapitulate the proposed
sequence of events in dietary-induced NAFLD. The sequence is instigated by increased
energy substrates, which promotes an extensive triglyceride accumulation in tandem
with enhanced acute respiration with a resultant rise in superoxide formation. The focus
is then to examine the long-term impact of this chain of events on mitochondrial
respiration, superoxide formation and metabolic alterations.
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It is salient to note that the effect of LPON on acute respiration reflects the synergistic
effect of all its components. Interestingly, despite their differences in (3-oxidation, the
acute treatment with either oleate or octanoate alone resulted in a similar rise in
respiration.
Second, the cellular viability after a 72-hour treatment with LPON remains unaltered.
Thus, we propose that LPON is a viable in vitro cellular steatosis model to dissect the
relationship between cellular steatosis, ROS and mitochondrial function.
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5. CHAPTER FIVE
THE CHRONIC EFFECT OF ENERGY SUBSTRATE EXPOSURE ON
MITOCHONDRIAL RESPIRATION
5.1. Introduction
There is robust evidence to support mitochondrial impairment and abnormal energy
homeostasis in NAFLD (32, 40, 62-64, 124). This evidence has been predominantly
inferred from steatohepatitis, thus leaving an uncertainty as to whether similar events
can also occur with simple steatosis. Furthermore, it is unclear whether increased
hepatic fat content can contribute to the mitochondrial dysfunction. Yet, reduction in
hepatic triglyceride accumulation is often construed as a marker of improvement in
NAFLD.
Oxidative stress is thought to be the crux of molecular events leading to mitochondrial
dysfunction (32, 40, 46, 92). In support of this, intracellular antioxidant, N-
acetylcysteine (NAC) has been shown to enhance mitochondrial function in adipocytes,
cardiac and skeletal muscle (98-100). Similarly, NAC prevents the development of
cirrhosis, ameliorates steatohepatitis and improves insulin resistance in hepatocytes (85,
125, 126). However, the effects of NAC on hepatic mitochondrial respiration
particularly in the presence of triglyceride accumulation remain unclear.
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We have previously shown that the combination of energy substrates, lactate, pyruvate,
octanoate and ammonia (LPON) acutely increased respiration leading to enhanced
mitochondrial superoxide formation; a sequence of events akin to that proposed to
occur in dietary-induced NAFLD. In this chapter, we examine the effect of chronic
LPON exposure on mitochondrial respiration. More important, we address a
fundamental question: does steatosis per se exert deleterious effects on mitochondrial
function?
The aims of this chapter are:
1. To examine the effect of prolonged LPON treatment on mitochondrial
respiration
2. To determine the impact of triglycerideper se in modulating respiration.
3. To investigate whether a reduction in steatosis would improve mitochondrial
function.
4. To examine whether energy substrates would alter mitochondrial structure.
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5.2. Methods
5.2.1. Cell respiration in treated cells
Confluent C3A cells grown in 25cm2 flasks were treated with the specified combination
of energy substrates for 72 hours. Cells were rinsed with HBSS, trypsinized and
centrifuged for 2 minutes. Cells were resuspended in MEME with FBS (2ml) and
counted to obtain 0.5xl06 cells in single suspension. Cells were added to each well of
the BD™ Oxygen Biosensor 96-well plate containing HBSS, HBSS+LPON and
HBSS+LPON+DNP (250pM). The fluorescent plate was read using CytoFluor Reader
Series 4000 for 40 cycles, for 40 minutes (excitation at 485nm and emission at 590nm).
The respiration rates were measured from the linear portion of the slope of fluorescence
rise. Data are presented as fold of change from the untreated cells or as arbitrary
fluorescent unit (AFU).
5.2.2. The effect ofN-acetylcysteine (NAC) on respiration
We examined the effect of NAC (lOmM) on triglyceride accumulation and cell
respiration in LPON treated cells. C3A cells grown in six-well plates were
simultaneously treated with LPON and NAC for 72 hours. Intracellular triglyceride was
quantified as described in section 3.2.2 and normalised to the total protein content. Cell
respiration was determined as described in section 5.2.1.
5.2.3. The effect of metformin on respiration and triglyceride accumulation
Although metformin has been widely used in the treatment of Type 2 diabetes, its
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mechanism of action remains unclear. Recent evidence has suggested that some of its
effect may have been mediated by adenosine monophosphate activated protein kinase
(AMPK) (127). This mechanism has also been proposed to underlie its lowering of
triglyceride in HepG2 cells (128). In this study, we used metformin (50nM-2mM) to
induce triglyceride reduction in LPON treated cells. Cells grown in six-well plates were
simultaneously treated with LPON and metformin at specified concentrations for 72
hours. Intracellular triglyceride was determined as described in section 3.2.2 and
normalised to the total protein content. Cell respiration was determined as described in
section 5.2.1. The effect of metformin on cell viability was determined as described in
section 2.1.6.
5.2.4. Cytosolic and mitochondrial NADH/NAD+ ratio
Decreased mitochondrial respiration impairs NADH oxidation to NAD+. Thus,
NADH/NAD+ ratio is influenced by mitochondrial respiration as well as by the rate of
NADH formation. Mitochondrial and cytosolic NADH/NAD+ ratios were determined
from the ratio of (3-hydroxybutyrate to acetoacetate and the ratio of lactate to pyruvate
respectively. Lactate, pyruvate, [3-hydroxybutyrate, and acetoacetate in the culture
medium were measured using Bergmeyer's enzymatic methods (129). This method
allows immediate measurements at the end of the treatment, as (3-hydroxybutyrate, in
particular, is an unstable compound. Briefly, acetoacetate concentration is determined
from the NADH consumed by (3-hydroxybutyrate dehydrogenase in the reaction:
Acetoacetate + NADH -» (3 -hydroxybutyrate +NAD+
Conversely, (3-hydroxybutyrate concentration corresponds to NADH produced. The
assays for acetoacetate (1 ml of 0.12mg of NADH for 1ml of PBS (with calcium and
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magnesium)) and (3-hydroxybutyrate (NAD+ (50mg), glycine (3g), water (100ml), hydrate
hydrazine (2ml) and LDH (lOOpl)) were added to aliquoted sample (200pl) and
homogenized. The baseline NADH was determined using spectrophotometer set at
340nm (the A.max for NADH). (3-Hydroxybutyrate dehydrogenase (lOpl) was then added
to each sample and the second spectrophotometer analysis was performed after 60
minutes.
Similarly, based on the reaction catalyzed by lactate dehydrogenase (LDH):
Lactate + NAD+—> Pyruvate + NADH + H+
lactate concentration corresponds to NADH produced whereas pyruvate concentration
is proportional to NADH consumed. For lactate measurements, the assay (NAD+
(50mg), glycine (3g), water (100ml), hydrate hydrazine (2ml) and LDH (100pi)) was
added to the sample (lOpl). The samples were homogenised and left for 90 minutes at
room temperature before spectrophotometer analysis. For pyruvate, the assay (NADH+
0.12mg for 1ml of PBS) was added to the sample (50pi) and homogenised before the
first spectrophotometer analysis. LDH (lOpl) was then added to each sample and the
second analysis was performed after 15 minutes.
5.2.5. Electron microscopy
To examine whether treatment with energy substrates altered mitochondrial structure,
treated cells were prepared for electron microscopy as described in section 3.2.4.
Mitochondria from four separate images from different sections were analyzed. The
outline of the mitochondria was traced individually to determine the cross-sectional area
using ImageJ. The scale was set to pm using the scale bar on the images as reference.
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5.3. Results
5.3.1. Basal mitochondrial respiration diminishes with LPON
We have shown that LPON resulted in acute rise in respiration. Here, the chronic
impact of LPON on basal respiration was determined. Because LPON resulted in
similar triglyceride accumulation but contrasting acute respiration to that seen with
oleate, we next focused on the following groups; oleate, LPON and untreated (control).
Additionally, lipid accumulation with oleate has been shown previously to have a
relatively low ROS formation (85, 107). To examine the effect of ROS on mitochondrial
function, cell respiration was also measured in additional cells that were concomitantly
treated with LPON and NAC (lOmM) for 72 hours. To further confirm the role of
ROS, we have included LPON cells treated simultaneously with another antioxidant, a-
tocopherol (0.4mM) for the entire treatment period.
Figure 5.3.1 shows that the acute rise in cell respiration observed with LPON was not
sustained; respiration with LPON at 72 hours was significantly lower than the untreated
cells. Despite the contrasting triglyceride accumulation, basal respiration was similar in
the oleate and untreated cells. Furthermore, as demonstrated in Figure 5.3.1, both
antioxidants preserved basal respiration in LPON treated cells. Respiration was 62%
and 53% higher in LPON cells that were treated simultaneously with NAC and cx-















Figure 5.3.1. Basal respiration in cells concomitantly treated with LPON and
NAC or a-tocopherol.
BD™ Oxygen Biosensor System was used to determine basal cell respiration as
described in section 5.2.1. Additional cells were simultaneously treated with LPON and
NAC or a-tocopherol for 72 hours. The fluorescent plates were read in CytoFluor
Reader Series 4000 for 40 cycles, for 40 minutes. Cell respiration was measured from
the linear portion of the slope of fluorescence rise. Data are presented as mean ± SEM;
P<0.0001; ***P<0.001,**P<0.01; NAC, N-acetylcysteine; TOCO, a-tocopherol.
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5.3.2. NAC restores substrate-induced respiration
In human NAFLD, oxidative stress is often compounded by an ongoing surge of
energy substrates. Thus, to examine the impact of further energy substrate exposure on
LPON treated cells; HBSS containing LPON was added to all groups immediately
before measurement of cell respiration. Further LPON would also confirm that the
reduction in basal respiration observed with LPON is neither attributable to decreased
substrate availability nor it is related to a suboptimal intermediary metabolism.
All groups demonstrated increased respiration with further LPON (Figure 5.3.2).
However, respiration for the LPON-pretreated cells remained lower than the untreated
cells. The combination of LPON with NAC or a-tocopherol restored cell respiration by
25% and 20% respectively, when compared with LPON treatment alone (Figure 5.3.2).
Interestingly, oleate treated cells also had lower substrate-induced respiration than the
untreated cells, but was still significantly higher when compared with LPON.
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Figure 5.3.2. Substrate-induced respiration in treated cells.
Further LPON was added to all groups prior to the measurement of respiration using
BD™ Oxygen Biosensor System as described in section 5.2.1. The fluorescent plates
were read in CytoFluor Reader Series 4000 for 40 cycles, for 40 minutes. Cell respiration
was measured from the linear portion of the slope of fluorescence rise. Data are
presented as mean ± SEM; P<0.0001; ***?<0.001, **P<0.01, *P<0.05; NAC, N-
acetylcysteine; TOCO, a-tocopherol.
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5.3.3. NAC does not ameliorate mitochondrial chain impairment
To examine the maximal capacity of mitochondrial respiratory chain, DNP was added
to all treated groups. DNP-induced uncoupling dissipates mitochondrial proton
gradient. This forces a maximal rise in respiration to preserve the gradient, essential to
maintain ATP formation. In the presence of DNP, the rise in cell respiration was
significantly lower with the LPON-treated cells when compared with the untreated cells,
suggesting decreased mitochondrial respiratory chain capacity. In contrast, the rise in
respiration induced by DNP with oleate, LP, LPO and octanoate were comparable to
that seen with the control cells (Figure 5.3.3 Panel A), showing an overall lack of impact
on the respiratory chain under these conditions. Interestingly, neither NAC nor (X-




Figure 5.3.3. Impaired maximal mitochondrial chain capacity with LPON.
A, Respiration in treated cells suspended in HBSS+LPON+2,4 dinitrophenol (DNP); B,
Respiration in cells treated simultaneously with NAC and a-tocopherol in the presence
of LPON+DNP. Separate groups of LPON cells were simultaneously treated with
NAC (lOmM) or of a-tocopherol (0.4mM) for 72 hours. Cells in single suspension were
added to BD™ Oxygen Biosensor 96-well plate containing LPON+DNP (250pM). The
fluorescent plates were then read in CytoFluor Reader Series 4000 for 40 cycles, for 40
minutes. Cell respiration was measured from the linear portion of the slope of
fluorescence rise. Data are presented as mean ± SEM; A, P=0.0003; B, P—0.0009;
**P<0.01, *P<0.05; NAC, N-acetylcysteine; TOCO, a-tocopherol.
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5.3.4. NAC does not reduce triglyceride accumulation
Next, to examine whether the recovery in cell respiration with NAC was associated with
a reduction in triglyceride accumulation, triglyceride concentrations in cells co-treated
with LPON and NAC were measured after a 72-hour treatment. The addition of NAC
to LPON did not alter triglyceride concentration (LPON 235.3 ± 12.2 vs LPON+NAC
237.3 ± 7.2 pg/g of total protein, P=0.9).
5.3.5. The effect of triglyceride reduction induced by metformin on respiration
The reduction in triglyceride is often construed as a marker of improvement in
NAFLD. However, it is still unclear whether a reduction in triglyceride per se has
beneficial impact on mitochondrial function. Metformin has been shown to decrease
triglyceride accumulation in HepG2 cells (128). Using metformin concentrations
previously shown to decrease triglyceride accumulation, we examined whether the
triglyceride reduction would improve mitochondrial function in LPON treated cells
(128).
5.3.5.1. Metformin does not affect cell viability in LPON treated cells
Cell viability was not compromised by metformin (50nM-2mM) as evidenced by the




Figure 5.3.5.1. Cell viability in cells treated with metformin and LPON.
Percentage of intracellular LDH retention was determined in cells that have been
simultaneously treated with LPON+metformin (50nM-2mM) after 72 hour using the
method described in section 2.1.6. Data are presented as mean ± SEM; P<0.0001;
*"P<0.001,"P<0.01, *P<0.05.
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5.3.5.2. Triglyceride reduction with metformin does not improved respiration
To induce triglyceride reduction, cells were treated with LPON+metformin (50nM-
2mM) for the treatment duration. Figure 5.3.5.2 Panel A shows that the concomitant
treatment with metformin at the concentration of 0.5, 1 and 2mM resulted in lower
triglyceride concentration in LPON cells when compared with LPON treatment alone.
However, the significant reduction in triglyceride with metformin (2mM) did not
improve respiration in LPON cells. As shown in Figure 5.3.5.2 Panel B, basal




Figure 5.3.5.2. The effect of metformin on triglyceride and basal respiration in
LPON treated cells.
A, Triglyceride concentrations in cells treated with LPON+metformin; B, Basal
respiration in cells simultaneously treated with LPON+metformin (2mM). A, Cells were
treated with LPON+metformin at specified concentrations for 72 hours. Intracellular
triglyceride accumulation was determined as described in section 3.2.2 and normalized
to total protein content as outlined in section 2.2.5. Data are presented as mean ± SEM;
P<0.0001; ***P<0.001 vs untreated; ®P<0.001, §P<0.05 vs LPON. B, To investigate
whether the reduction in triglyceride accumulation would improve mitochondrial
function, basal respiration (described in section 5.2.1) was measured in cells treated with
LPON and metformin (2mM) for 72 hours. Data are presented as mean ± SEM;
P=0.008; *"P<0.001,**P<0.01, ><0.05 vs untreated.
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5.3.5.3. Reduced NADH oxidation with metformin
Impaired mitochondrial respiration can reduce NADH oxidation to NAD+ leading to a
rise in mitochondrial NADH/NAD+ ratio. This reduces the shuttling of NADH from
cytosolic into the mitochondria. Thus, the cytosolic NADH/NAD+ ratio would also
rise in parallel to the increase in mitochondrial NADH/NAD+ ratio. To investigate
whether LPON+metformin reduces NADH oxidation, the ratios of (3-hydroxybutyrate
to acetoacetate (mitochondrial NADH/NAD+ ratio) and lactate to pyruvate ratio
(cytosolic NADH/NAD+ ratio) were determined. Figure 5.3.5.3 Panel A shows a
progressive rise in mitochondrial NADH/NAD+ ratio mirroring the rising
concentrations of metformin suggesting a dose-dependent effect of metformin on
mitochondrial respiratory chain. Metformin at 1 and 2mM increased mitochondrial
NADH/NAD+ ratio in LPON treated cells by two- and four-fold respectively. Panel B
shows that cytosolic NADH/NAD+ ratio rose with the increasing concentrations of
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Figure 5.3.5.3. NADH/NAD+ ratio in cells treated LPON and metformin.
A, Mitochondrial NADH/NAD+ ratio; B, Cytosolic NADH/NAD+ ratio. To
investigate whether decreased respiration with metformin was paralleled by increased
NADH/NAD+ ratio, |3-hydroxybutyrate to acetoacetate (mitochondrial
NADH/NAD+) and lactate to pyruvate ratio (cytosolic NADH/NAD+) were
determined. Data are presented as mean ± SEM; A, P<0.0001; *"P<0.001 vs untreated;
§§§P<0.001 vs LPON; B, P<0.0001; ***P<0.001 vs untreated, ®P<0.001 vs
LPON+metformin (2mM).
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5.3.6. Altered mitochondrial structure is most pronouncedwith LPON
Impaired mitochondrial function in NAFLD is often paralleled by alterations in
mitochondrial structure, the most striking of which, is the development of enlarged
mitochondria (32, 77, 78). Transmission electron microscopy revealed that
mitochondrial cross-sectional area was lower in LPON when compared to oleate or the
untreated group (Figure 5.3.6.1). Figure 5.3.6.2 demonstrates representative electron
microscopy images of treated cells viewed at the magnification x8400. The cristae in
octanoate, oleate and treated cells, but not LPON, were distinct. Figure 5.3.6.3
represents electron microscopy images of mitochondria from cells treated with LPON
and octanoate. Despite the similarities in the cross-sectional area, mitochondrial
morphology was different. In LPON treated cells, the mitochondria were elongated and






Figure 5.3.6.1. Cross-sectional area of the mitochondria in treated cells.
C3A cells treated for 72 hours were prepared for electron microscopy as described in
section 3.2.4. Cross-sectional area of the mitochondria from four different random
sections of each group was measured using ImageJ. Data are presented as mean ± SEM;
P=0.04.
107
Figure 5.3.6.2. Electron microscopy images of mitochondria in treated cells.
A, Untreated; B, LPON; C, Octanoate; D, Oleate. C3A cells were treated for 72 hours
and prepared for electron microscopy as previously described in section 3.2.4; (m,
mitochondria; Id, lipid droplets and n, nucleus; magnification x8400).
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Figure 5.3.6.3. Eiectron microscopy images of mitochondria in treated ceiis.
A, LPON; B, Octanoate; (white arrows, mitochondria; n, nucleus; lipid droplets;
magnification x2100).
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5.4. Discussion and conclusion
This chapter is focused on the effect of enhanced mitochondrial respiration and
increased superoxide formation on mitochondrial respiration. More important, we
address a fundamental question: does steatosis in the absence of ROS exert a deleterious
effect on mitochondrial function?
The main findings of this chapter are:
1. Prolonged LPON treatment led to a significant reduction in basal and substrate-
induced respiration, as well as diminished mitochondrial chain capacity.
2. Cell respiration was improved in cells treated simultaneously with LPON and
NAC or a-tocopherol.
3. Reduction in triglyceride accumulation with metformin did not improve
mitochondrial function.
4. Impaired mitochondrial respiration with LPON was associated with altered
mitochondrial structure.
These data highlight two important points. First, the capacity of an energy substrate to
generate ROS rather than its ability to induce cellular steatosis is the determinant to the
subsequent mitochondrial function. In support of this, respiration was preserved with
oleate treated cells despite similar triglyceride concentration to that seen in cells treated
with LPON. Sustained basal and substrate-induced respiration in the presence of the
antioxidants further suggests ROS involvement in promoting the mitochondrial
impairment. Moreover, the mitochondrial morphological changes observed with LPON
are similar to the alterations previously described in the presence of oxidative stress (32,
82).
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Second, a reduction in intracellular triglyceride does not necessarily lead to an
improvement in mitochondrial function. We have shown that metformin did not restore
mitochondrial function despite the reduction in triglyceride accumulation. Indeed, the
dose-dependent rise in mitochondrial and cytosolic NADH/NAD+ ratio with
metformin are consistent with a progressive decline in NADH oxidation, which can
occur with impaired mitochondrial respiration. It is worth noting that the overall
triglyceride concentrations in Figure 5.3.5.2 were lower than previously observed (Figure
3.3.3). These variations might have been attributable to the differences in cell passage; a
reduction in de novo lipogenesis in later passage has been previously shown in human
fibroblasts (130).
Taken together, our data suggest that the enhanced ROS formation with LPON leads to
a significant mitochondrial impairment. This is in accord with several previous studies
(32, 59). Thus, the sequence of events instigated by increased energy substrates with
LPON is similar to that observed in human and animal model with NAFLD; increased
respiration with concomitant rise in ROS formation culminates in altered mitochondrial
function. More important, our data address a fundamental point; in the absence of ROS,
triglyceride accumulation does not impair mitochondrial respiration.
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6. CHAPTER SIX
LPON CELLULAR STEATOSIS IS CHARACTERIZED BY CHRONIC
OXIDATIVE STRESS
6.1. Introduction
The association between mitochondrial impairment with enhanced ROS formation is
well established (75). The accepted hypothesis is that ROS promote mitochondrial
dysfunction, which in turn, perpetuates ROS formation, creating a vicious cycle thus
promoting chronic oxidative stress, the hallmark of dietary-induced steatohepatitis.
Thus far, we have shown in vitro that enhanced ROS formation, rather than intracellular
triglyceride accumulation per se, leads to impaired mitochondrial respiration. In this
chapter, we examine whether altered mitochondrial respiration in the LPON cellular
steatosis model would lead to further ROS formation and oxidative stress. We have
postulated that decreased mitochondrial respiration with LPON would promote further
ROS release driven by the presumed decline in NADH oxidation. It is anticipated that
the heightened ROS formation would result in oxidative stress mirrored by enhanced
lipid peroxidation.
The extent of lipid peroxidation is a particularly reliable marker of oxidative stress in
NAFLD (46). Lipid is abundant in NAFLD. Thus, the potential for lipid peroxidation
can be substantial. The resultant reactive aldehydes can instigate the release of pro¬
inflammatory cytokines. Furthermore, the peroxidation byproducts can undergo further
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oxidative process, which generate additional ROS. Increased polyunsaturated fatty acids
(PUFA) peroxidation has also been associated with enhanced formation of dicarboxylic
acid from (O-oxidation (131, 132). In turn, dicarboxylic acid enters the peroxisomal (3-
oxidation pathway (133, 134). Unlike mitochondrial (3-oxidation, peroxisomal (3-
oxidation is not associated with ATP production but instead, each sequence generates a
myriad ofROS predominantly H202.
The aims of this chapter are:
1. To examine whether the reduction in mitochondrial respiration would modulate
superoxide formation.
2. To determine whether the acute rise in superoxide formation with LPON would
lead to increased oxidative stress.
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6.2. Methods
6.2.1. Measurement of superoxide formation
Mitochondrial superoxide production was measured using the live-cell permeable
fluorescent probe MitoSOX™ as described in 4.2.2. For fluorescent microscopy, cells
were treated with specified energy substrates in two-chamber slides until 70% confluent.
Treated C3A cells were then incubated with MitoSOX™ for 45 minutes at 37°C. The
supernatant was then removed and cells were rinsed, before the addition of 500pl of
HBSS into each chamber. The slides were kept at 37°C and viewed under fluorescent
microscopy. Phase contrast and fluorescent field images were obtained and then merged
using image editor software, Photoshop CS4, (Adobe Systems Incorporated, San Jose,
CA, USA). Fluorescence intensity from each image was analysed using ImageJ. For
FACS analysis, treated cells were trypsinized for 5 minutes, rinsed with HBSS and
centrifuged. Cells were resuspended in HBSS or LPON to determine the superoxide
formation during basal or substrate-induced respiration respectively, before FACS
analysis (FACS Calibur™, BD Biosciences, CA, USA).
6.2.2. Metabolomics profiling of oxidative stress markers
Metabolomics is an emerging analytical method to identify and quantify metabolites in a
biological system. Oxidative stress markers including the end products of lipid
peroxidation can be identified using this method. For metabolomics, treated C3A cells
were centrifuged (lOOOg) for 10 minutes at 37°C. The cell pellet was resuspended in 1ml
of supernatant, transferred to a 1.5ml tube, and the final pellet was obtained by further
centrifugation (3000^) for 5 minutes followed by a complete removal of supernatant.
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Metabolites were extracted from the cell pellet by the addition of 200pl of
chloroform/methanol/water (1:3:1) with vigorous mixing for 1 hour at 4°C.
Precipitated proteins and cellular debris were removed by centrifugation (13000g) for 5
minutes. Supernatant was kept at —80°C until liquid chromatography (LC)-mass
spectrometry (MS) analysis within 2 weeks. Additional control samples included cell-free
growth medium and extraction solvent served as blanks.
The LC separation was performed using hydrophilic interaction chromatography with a
ZIC-HILIC 150 x 4.6 mm, 5(am column (Merck Sequant, Umea, Sweden), operated by
an UltiMate 3000 RSLC liquid chromatography system (Dionex, Camberley, Surrey,
UK). The separation consisted of a linear gradient from 80% B to 20% B over 30
minutes, followed by an 8-minute wash with 5% B, and 8-minute reequilibration with
80% B, where solvent B was 0.08% formic acid in acetonitrile, and solvent A was 0.1%
formic acid in water. The flow rate was 300pU/minute, column temperature 20°C,
injection volume lOjaL, and samples were maintained at 4°C. The mass spectrometry
was performed using an Orbitrap Exactive (Thermo Fisher Scientific, Hemel
Hempstead, UK) with a HESI 2 probe. The spectrometer was operated in polarity
switching mode, with the following settings: resolution 50,000 m/z range 70—1400.
Ionisation voltages were +4.5 kV and —3.5 kV in positive and negative modes
respectively.
Raw LC-MS data were processed with a combination of XCMS Centwave for peak
picking (http://metlin.scripps.edu/xcms/), and mzMatch for alignment and annotation
of related peaks (http://mzmatch.sourceforge.net/). Metabolite identification was
performed by matching masses and retention times to the database with mass accuracy
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window of 3 ppm (if two formulae were within 3ppm the closest match was taken) and
RT window of 35% (by in-house VBA scripts). Additional automated noise and MS
artifact filtering procedures were applied to remove peak sets that contained: 1) peaks
that were present at equal or higher abundance in the blank solvent samples 2) all peaks
lower than the intensity threshold (10,000) 3) shoulder or duplicate peaks within the
same mass (3 ppm) and retention time (0.2 min) window 4) common MS artifacts 5)
irreproducible intensities (relative standard deviation > 0.5) across replicate samples.
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6.3. Results
6.3.1. Basal mitochondrial superoxide is diminishedwith chronic LPON
exposure
We have previously shown that basal respiration with LPON was significantly
diminished after 72 hours. To examine whether the reduction in basal respiration would
affect superoxide formation, cells were labeled with MitoSOX™ for superoxide
quantification. Figure 6.3.1 Panel A and B consist of representative fluorescent
microscopy images ofmitochondrial superoxide formation in the untreated and LPON
treated cells respectively. Panel C shows the quantification of fluorescent area using
ImageJ. Basal mitochondrial superoxide formation after a 72-hour treatment was similar
between LPON and the untreated cells. This finding was further confirmed by FACS
analysis (Panel D). Despite the contrasting basal respiration, mitochondrial superoxide
formation was similar in LPON and the untreated cells.
6.3.2. Increased mitochondrial superoxide with further LPON exposure
Substrate-driven respiration was also diminished in LPON treated cells. Therefore, we
examined the magnitude of superoxide formation during substrate-driven respiration.
Treated cells labeled with MitoSOX™ were resuspended in further LPON prior to
FACS analysis. As demonstrated in Figure 6.3.2, there was a dramatic rise in the peak
fluorescence intensity with LPON suggesting that superoxide formation were
significantly upregulated in these cells in the presence of further energy substrates
despite the reduction in respiration. In contrast, superoxide formation with oleate
treated cells remained similar to that seen with the untreated cells.
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Figure 6.3.1. Basal mitochondrial superoxide formation in treated cells.
A, Untreated cells; B, LPON treated cells, labeled with MitoSOX1 M viewed under
fluorescent microscopy; C, ImageJ analysis of fluorescent area in cells labeled with
MitoSOX1M; D, Peak fluorescence in treated groups quantified by FACS. A-C, Cells
treated in two-chamber slides for 72 hours were incubated in MitoSOX1M for 45
minutes before fluorescent microscopy (magnification xlO). Fluorescent area was
analysed using ImageJ. Data are presented as mean ± SEM; P=0.15 (unpaired /-test). D,
Cells treated in 25cm2 flasks were trypsinized and incubated with MitoSOX1M for 45
minutes. Cells were then rinsed, centrifuged and resuspended in HBSS. Data are






Figure 6.3.2. Mitochondrial superoxide formation during substrate driven
respiration.
Cells treated in 25cm2 flasks were trypsinized and incubated with MitoSOX™ for 45
minutes at 37°C. Cells were then rinsed, centrifuged and resuspended in further LPON
before FACS analysis. Data are presented as mean ± SEM; P—0.005, **P<0.01.
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6.3.3. LPON is associated with oxidative stress
Next, we determined whether LPON was associated with increased oxidative stress.
The byproduct of lipid peroxidation has been proposed to be a reliable marker of
oxidative stress in vivo and in vitro. In oxidative stress, the formation of lipid
hydroperoxides is enhanced and their enzymatic or non-enzymatic alterations would
produce intermediates such as reactive aldehydes (46). Using metabolomics profiling,
lipid peroxidation intermediates were identified and quantified. Given the contrasting
respiration between LPON and oleate (despite similar triglyceride accumulation), we
focused on the following groups; untreated (control), LPON and oleate.
6.3.3.1. Enhanced lipid peroxidation with LPON
A total of six metabolites of fatty acid-derived aldehydes were identified (Figure 6.3.3.1).
As shown in Figure 6.3.3.1, LPON treated cells had a non-statistically significant rise in
4-HNE and its precursor, 3-nonenal, when compared with oleate. In contrast, the levels
of pentadecanal, 2-hexenal and 2,4-octadienal are significantly higher with LPON than









































Figure 6.3.3.1. Lipid peroxidation intermediates in treated cells.
A, 4-HNE; B, 3-Nonenal; C, Pentadecanal; D, 2-Hexenal; E, 2,4-Octadienal; F, 2,4-
Heptadienal. Metabolites were identified using metabolomics in cells treated with
specified substrates for 72 hours. Data are presented as mean ± SD; P values: A, 0.13;
B, 0.12; C, 0.04; D, 0.001; E, <0.0001; F, 0.72; ***P<0.001, "P<0.01, *P<0.05.
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6.3.3.2. Isoprostane is increased with LPON
Isoprostanes are prostaglandin-like substances produced primarily by non-enzymatic
peroxidation of arachidonic acid. Among the isoprostanes discovered to date, F2-
isoprostanes, the isomeric compounds of cyclooxygenase-derived PGF2a, have been
regarded as the most reliable marker of oxidative stress/lipid peroxidation status in vivo
(135, 136). Furthermore, F2-isoprostanes have been implicated in the pathogenesis of
hepatic fibrosis (137). Using the metabolomics approach, we identified a metabolite
that corresponded to F2-isoprostane. Figure 6.3.3.2 represents the concentration of
9S,llR,15S-trihydroxy-2,3-dinor-5Z,13E-prostadienoic acid-cyclo (8S,12R) (2,3-dinor-8-
iso-PGF2a), an F2-isoprostane, in treated cells. The concentration of 2,3-dinor-8-iso-



































Figure 6.3.3.2. The concentration of F2-isoprostane in treated cells.
F2-isoprostane is regarded as a reliable marker of oxidative stress in vivo. 9S,11 R,15S-
Trihydroxy-2,3-dinor-5Z,13E-prostadienoic acid-cyclo (8S,12R) (2,3-dinor-8-iso-
PGF2a), a metabolite of F2-isoprostane, was identified using metabolomics in treated
cells. Data are presented as mean ± SD; P=0.01, *P<0.01.
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6.3.3.3. Increased dicarboxylic acid concentrations with LPON
Medium and short chain dicarboxylic acids have also been proposed to be a marker of
oxidative stress (132). In NAFLD, measuring dicarboxylic acids as a marker of oxidative
stress can potentially provide an insight into |3-oxidative capacity; the presence of
dicarboxylic acid suggests mitochondrial (3-oxidation overload. Their presence also
heralds an ongoing ROS formation. The oxidation of dicarboxylic acids by peroxisomal
[3-oxidation generates a considerable amount of ROS. Additionally, dicarboxylic acids
have also been shown to diminish respiration (133). Using metabolomics analysis, a total
of 19 metabolites that corresponded to dicarboxylic acid were identified (Table 1). The
concentration of all nine medium chain (C8-C12)) dicarboxylic acids were significantly
higher with LPON when compared with the untreated or oleate (Table 6.3.3.3 and
Figure 6.3.3.3.1). Similarly, the levels of C13 and C14 dicarboxylic acid were higher with
LPON. Taken together, these findings are consistent with increased oxidative stress as
well as overwhelmed mitochondrial (3-oxidation. Interestingly, the concentrations of
very long chain dicarboxylic acids (>C16) were similar between LPON and the















C6H10O4 Ad ipate 0.31 0.46
C7H12O4 Heptanedioic acid 1.12 0.90
Medium chain (C8-C12)
C8H14O4 Suberic acid 1.29* 1.02
C10H18O4 Decanedioic acid 1.53* 0.99
C10H18O5 3-hydroxysebacic acid 1.51* 0.86
C11H20O4 Undecanedioic acid 1.41* 1.01
C12H20O4 Traumatic acid 2.43* 0.90
C12H22O4 Dodecanedioic acid 2.68* 0.97





C13H24O4 Brassilic acid 1.41* 1.01
C14H26O4 Tetradecanedioic acid 1.50* 0.86
C14H26O5 3-hydroxy-tetradecanedioic acid 1.56* 1.00
C16H30O4 Hexadecanedioic acid 1.10 0.92
C17H32O4 2-methyl-hexadecanedioic acid 1.26* 0.92
C20H38O4 Eicosanedioic acid 1.02 0.95
C21H40O4 Heneicosanedioic acid 0.90 1.14
C23H44O4 Tricosanedioic acid 0.98 0.97
C26H50O4 Hexacosanedioic acid 0.90 1.14
Table 6.3.3.3. Dicarboxylic acids concentrations in treated cells.
The concentration of dicarboxylic acid determined using metabolomics in treated cells.
<C8, short chain; C8-C12, medium chain; >C13, long chain dicarboxylic acids. Data




















































Figure 6.3.3.3.1. Increased dicarboxylic acids concentration in LPON cells.
Metabolites that corresponded to dicarboxylic acids were identified using metabolomics.
A, Suberic acid (P—0.002); B, Decanedioic acid (P<0.0001); C, 3-Hydroxysebacic acid
(P=0.001); D, Undecanedioic acid (P<0.0001); E, Traumatic acid (P<0.0001); F,
Dodecanedioic acid (P<0.0001); G, 3-Hydroxydodecanedioic acid (P<0.0001); H,
2E,4E,8E,10E-Dodecatetraenedioic acid (P=0.01); I, Brassilic acid (P<0.0001); J,
Tetradecanedioic acid (P<0.0001); K, 3-Hydroxytetradecanedioic acid (P<0.0001); L, 2-
Methylhexadecanedioic acid (P<0.0001). With the exception of 2-
methylhexadecanedioic acid, all were <C14. Data are presented as mean ± SD;
~P<0.001, "P<0.01, *P<0.05.
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6.4. Discussion and conclusion
This chapter examines whether the reduction in mitochondrial respiration observed in
the LPON in vitro model of cellular steatosis is associated further superoxide formation
and oxidative stress.
The main findings of this chapter are:
1. Basal mitochondrial superoxide formation was downregulated in parallel with
the diminished basal respiration with LPON.
2. Exposure to further energy substrates dramatically increased the superoxide
production in LPON treated cells.
3. Despite the downregulation of basal superoxide formation, LPON was
associated with increased lipid peroxidation and dicarboxylic acid formation
indicative of oxidative stress.
These data highlight four important points. First, the reduction in basal ROS after a 72-
hour treatment with LPON was unexpected. It was anticipated that diminished basal
respiration would have led to an increase in superoxide formation driven by the
potential reduction in NADH oxidation. It is possible that the initial surge of ROS may
have instigated metabolic adaptations to curb further ROS formation. Thus,
determining the modulators of mitochondrial ROS formation notably mitochondrial
membrane potential and NADH/NAD+ ratio would be instrumental in dissecting the
underlying mechanism.
Second, the capacity for ROS formation is actually enhanced in LPON treated cells.
This is evidenced by a significant rise in the substrate-induced ROS. It is likely that
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diminished mitochondrial respiration hinders the oxidation of NADH generated from
further energy substrates leading to a significant increase in NADH/NAD+ ratio. More
important, this indicates that further exposure to energy substrates can overcome any
potential mechanism responsible for minimizing ROS formation. This is particularly
relevant to human steatohepatitis where ongoing surge of energy substrates is likely to
occur.
The differences in the superoxide formation between cells treated with LPO and LPON
further emphasized that mitochondrial impairment, not triglyceride accumulation, is
responsible for sustaining oxidative stress. Treatment with LPO led to an extensive
triglyceride accumulation but with preserved mitochondrial respiration. This maintains
efficient NADH oxidation even in the presence of further energy substrates. Whether
these differences can be attributable to the presence of ammonia in LPON remains
unclear. However, mitochondrial respiration in cells that have been treated with the
combination of lactate, pyruvate, oleate and ammonia for 72 hours remains unaltered
(unpublished data from our group; data not shown). Further, metabolomic profiling on
these cells or cells treated with ammonia alone does not support the presence of
oxidative stress (unpublished data from our group; data not shown). Taken together,
these data suggest that the rise in ROS incurred by LPON represents a synergistic effect
of all its components rather than that of ammonia alone.
Third, despite the relatively low basal ROS formation, the evidence of oxidative stress is
already apparent in LPON cells as evidenced by the increased formation of fatty
aldehydes, dicarboxylic acids and isoprostane. This is likely to be attributable to the
acute rise in superoxide formation coupled with the abundance of substrates susceptible
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to peroxidation from the enhanced de novo lipogenesis.
Finally, increased dicarboxylic acid concentration with LPON highlight the presence of
fatty acid dysregulation that can occur with substrate overload. Enhanced dicarboxylic
acid formation suggests increased co-oxidation, a minor fatty acid oxidative pathway
inducible in the presence free fatty acid overload or in conditions that overwhelm
mitochondrial (3-oxidation. Additionally, dicarboxylic acids can act as a ligand of the
hepatic lipid sensor, PPAR-a, to induce all three fatty acid oxidative pathways; 00-
oxidation, peroxisomal ^-oxidation and the already strained mitochondrial ^-oxidation
with a resultant rise in ROS burden.
In conclusion, ROS beget more ROS. Although we have not demonstrated a sustain rise
in superoxide, the presence of excessive H2Oz (and potentially other ROS) from the (0-
and peroxisomal (3-oxidation cannot be excluded. Mitochondrial impairment only
serves to enhance the inherent capacity to form further ROS. This is likely to sustain




THE REGULATION OF MITOCHONDRIAL ROS FORMATION
7.1. Introduction
In the previous chapter, we have demonstrated an unanticipated downregulation of
basal ROS with LPON despite evidence to suggest mitochondrial impairment. This
raises the question whether adaptations to minimize ROS formation have already
occurred. In this chapter, we focus on factors that may have modulated the superoxide
formation in LPON treated cells.
As previously discussed, there are two main factors that regulate mitochondrial ROS
formation. First, ROS can be modulated by mitochondrial NADH/NAD+ ratio.
Increased concentration of the electron carrier, NADH, accelerates the formation of
superoxide. In normal mitochondria, such rise in NADH is swiftly met by an active
respiration, thus maintaining efficient NADH oxidation to lower the NADH/NAD+
ratio. Second, superoxide production is highly sensitive to the changes in mitochondrial
membrane potential (Af^. Increased A lI/m inhibits respiration; hence NADH
concentration rises, bolstering the superoxide formation. Conversely, a reduction in
mitochondrial A Wm either by an efficient ATP formation or through uncoupled
respiration mitigates superoxide formation.
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The aim of this chapter is to identify potential factors that may have modulated ROS in
treated cells, specifically:
1. Mitochondrial membrane potential (AlP^)




7.2.1. Determining mitochondrial membrane potential using JC-1
The lipophilic cationic probe, JC-1 (Invitrogen, NY, USA) can detect ATm in intact
cells. JC-1 forms multimers (J-aggregates) and monomers in the presence of high and
low A¥m respectively. The difference in the emission spectra between the monomer
form (green range (530nm)) and J aggregates (red-orange range (590nm)) allows the
assessment of A¥m using FACS and fluorescent microscopy. The level of A¥m can be
calculated from the ratio of median fluorescence intensity of red (detected in FL2
channel) to green (detected in FL1 channel). Thus, mitochondrial hyperpolarization is
indicated by an increase in the red to green fluorescence intensity ratio and vice versa.
For fluorescent microscopy, cells were grown and treated in two-chamber slides for 72
hours. Cells were labeled with 5pM ofJC-1 for 20 minutes at 37°C as adherent cells and
viewed under LSM510 fluorescent microscope. Fluorescent images were merged using
image editor software, Photoshop CS4, and the intensity was analysed using ImageJ.
Briefly, each image was set to a threshold, and the intensity was determined using
'analyze particle'. For FACS, C3A cells were grown and treated in 25cm2 flask. Stock
solution for JC-1 was prepared by adding 500pl of HBSS. Treated cells were rinsed and
incubated with 2ml of JC-1 for 20 minutes in 37°C. Cells were then trypsinized,
centrifuged and the supernatants were discarded. Cells were resuspended in 5ml of
HBSS and FACS analysis was performed.
7.2.2. Cell respiration in the presence of oligomycin
Confluent cells treated with the specified combination of energy substrates for 72 hours
were rinsed, trypsinised and centrifuged as described in section 5.2.3. Cells were
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resuspended in 2ml of MEME (with FBS) and were added to the BD™ Oxygen
Biosensor 96-well plate containing LPON+Oligomycin (5 |ig/ml). The fluorescent plate
was then read in CytoFluor Reader Series 4000 for 40 cycles, for 40 minutes.
Respiration was measured from the linear portion of the slope of fluorescence rise. Data
are presented as arbitrary fluorescent unit (AFU).
7.2.3. Mitochondrial and cytosolic NADH to NAD+ ratio
Mitochondrial and cytosolic NADH/NAD+ ratio were determined from the ratio of (3-
hydroxybutyrate to acetoacetate and lactate to pyruvate respectively, as described in
section 5.2.4. The presence of lactate and pyruvate in the LPON culture supernatant
would preclude any conclusive determination of cytosolic NADH/NAD+ ratio. For this
reason, treated cells were rinsed and allowed to reach a steady state for 24 hours in
MEME without additional FCS or energy substrates. Cells from all groups were then
incubated for 4 hours in PBS and octanoate (2mM) prior to the measurement of
mitochondrial and cytosolic NADH to NAD+ ratio.
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7.3. Results
7.3.1. Increased mitochondrial membrane potential with LPON
Using the probe JC-1, we determined the A by calculating the ratio of median
intensity of red to green fluorescence. Figure 7.3.1.1 demonstrates representative
fluorescent image of red (Panel A) and green (Panel B) from LPON treated cells labeled
with JC-1. These images were merged to highlight the red to green fluorescent intensity
ratio (Panel C). Figure 7.3.1.2 (Panel A to E) are merged images of treated cells. Panel F
shows that ImageJ analysis of the fluorescence intensity suggests higher A!Fm with
LPON than the untreated cells. Indeed, FACS analysis confirms this finding. As
demonstrated in Figure 7.3.1.3, LPON treatment led to increased when compared
with the untreated cells. In contrast, in oleate treated cells was unaltered. We have
also included separate groups of LPON cells that have been concomitantly treated with
NAC for the entire treatment. As shown in Figure 7.3.1.3, cells that have been treated
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Figure 7.3.1.1. Mitochondrial membrane potential (A^) in LPON treated cells.
A, Red fluorescent and B, Green fluorescent image viewed under fluorescent
microscopy; C, The fluorescent images merged to determine red to green fluorescent
ratio. The lipophilic cationic fluorescent probe, JC-1, was used to detect A¥m. Treated
cells in two-chamber slides were labeled with 5pM of JC-1 for 20 minutes at 37°C as
adherent cells. Labeled cells were then viewed under fluorescent microscopy. The ratio
of red-orange range (590nm) to green range (530nm) represents A!Fm. To this end, red
and green fluorescent images were merged using Adobe Photoshop software with




Figure 7.3.1.2. Mitochondrial membrane potential (A?^) in treated cells.
Merged fluorescent images of A, Untreated; B, Octanoate; C, LP; D, LPO; E, LPON
labeled with JC-1; F, Mean of red to green fluorescent intensity ratio obtained from the
images (Panel A-E) quantified using TmageJ as described in section 7.2.1. Cells were
grown and treated for 72 hours in two-chamber slides. Cells were then labeled with
5pM ofJC-1 for 20 minutes at 37°C as adherent cells as described in section 7.2.1.
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Figure 7.3.1.3. Fluorescent intensity from JC-1 labeled cells quantified by FACS.
Treated cells were trypsinlzed and labeled with JC-1. Cells were rinsed, centrifuged and
resuspended in HBSS immediately before FACS analysis. is determined by
calculating the ratio of median intensity of red to green fluorescence (FL2/FL1). Data
are presented as mean ± SEM; P=0.003; **P<0.01,*P<0.05.
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7.3.2. LPON increases cytosolic but not mitochondrial NADH/NAD+ ratio
Next, we examined the impact of LPON on NADH/NAD+ ratio. We anticipated that
mitochondrial impairment with LPON would promote an increase in NADH/NAD+
ratio. However, the previously demonstrated low basal superoxide formation with
LPON is not consistent with increased NADH concentration. Indeed, as demonstrated
in Figure 7.3.2. Panel A, mitochondrial NADH/NAD+ ratio with LPON was similar to
that seen in the untreated cells. This may explain decreased basal ROS formation but is
not expected in the presence of diminished respiration. Figure 7.3.2. Panel B
demonstrates a more reduced cytosolic compartment with LPON when compared with
the untreated cells suggesting decreased NADH shuttling into the mitochondria, which
is expected to occur in mitochondrial impairment.
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Figure 7.3.2. Mitochondrial and cytosolic NADH/NAD+ ratio in treated cells.
A, Mitochondrial NADH/NAD+ ratio; B, Cytosolic NADH/NAD+ ratio. To
determine the mitochondrial and cytosolic NADH/NAD+ ratios, (3-hydroxybutyrate to
acetoacetate and lactate to pyruvate ratios were measured after a 72-hour treatment as
described in section 7.2.3. Data are presented as mean ± SEM; A, P—0.03; *P<0.05; B,
P=0.04; *P<0.05.
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7.3.3. Further exposure to energy substrates enhances NADH/NAD+ ratio
We have previously shown that the addition of further energy substrates resulted in a
significant rise in superoxide formation in LPON treated cells (Figure 6.3.2). Because
steatohepatitis is charactemed by chronic oxidative stress, which in part, is sustained by
the recurrent surge of energy substrates, we examined the impact of further LPON on
mitochondrial NADH/NAD+ ratio. Additionally, to dissect the individual contribution
from each component of LPON, we focused on the following groups: LPON, LP,
octanoate and untreated cells (control). Treated cells were rinsed and fresh culture
media as specified for each group were added. Cells were treated for another 72 hours.
(3-Hydroxybutyrate to acetoacetate and lactate to pyruvate ratios were determined as
described in section 6.2.5. Figure 7.3.3 demonstrates higher mitochondrial
NADH/NAD+ ratio with LPON when compared with the untreated cells indicating
decreased NADH oxidation at the level of respiratory chain. The finding of higher
mitochondrial NADH/NAD+ ratio with LPON than either LP or octanoate suggests
the synergistic effect of the energy substrates in sustaining the reduction in NADH
oxidation. In contrast, cytosolic NADH/NAD+ ratio was unexpectedly similar in all
groups. It is possible that the similarity reflects the eventual decline in cytosolic NADH
formation with metabolic changes such as gluconeogenesis, known to occur in
association with mitochondrial impairment (98).
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Figure 7.3.3. NADH/NAD+ ratio in treated cells with further energy substrate.
A, Mitochondrial; B, Cytosolic NADH/NAD+ ratio in treated cells exposed to further
energy substrates. Fresh media were added to the treated cells and left for another 72
hours. Cells were then rinsed and incubated in fresh MEME (without energy substrates
or FCS) for 24 hours, before a 4-hour incubation with octanoate (4mM) in PBS. (3-
Flydroxybutyrate to acetoacetate and lactate to pyruvate ratio were determined as
described in section 6.2.5. Data are presented as mean ± SEM; A, P<0.0001; B, P—0.52;
~P<0.001, **P<0.01, *P<0.05.
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7.3.4. NAC and a-tocopherol enhances uncoupled respiration
Another factor that can influence the level of superoxide formation is the modulation of
AlFm by proton leak. Superoxide, free fatty acids and lipid peroxidation intermediates
such as HNE, have all been shown to induce proton leak by activating uncoupling
proteins (UCP) (70-73). UCP allows proton slipping into the matrix independent of
ATP synthase thus lowering the AWm, diminishing superoxide formation and inducing
the compensatory uncoupled respiration in the process. To examine whether proton
leak influenced superoxide formation in the treated cells, respiration were measured in
the presence of oligomycin. Oligomycin blocks the passage of protons through the
ATP synthase leading to mitochondrial hyperpolarization thus abolishing respiration.
Therefore, the respiratory activity is directly proportional to the proton leak.
In the presence of oligomycin, cell respiration was significantly diminished (Figure 7.3.4
Panel A). However, the degree of uncoupled respiration differed among the groups
(Figure 7.3.4 Panel B). LPON showed a non-statistically significant trend of higher
uncoupled respiration than oleate or untreated cells. Intriguingly, simultaneous
treatment with LPON and either NAC or a-tocopherol had resulted in a significantly
higher uncoupled respiration than the untreated cells.
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A
Figure 7.3.4. Cell respiration in the presence of oligomycin.
A, The effect of oligomycin on respiration; grey bar, cell respiring on LPON alone;
black bar, cell respiring on LPON+oligomycin (5mg/ml); B, The varying degrees of
uncoupled respiration in treated cells respiring on LPON+oligomycin (represented by
black bars in A). Cells in single suspension were added to BD™ Oxygen Biosensor 96-
well containing LPON+oligomycin. The fluorescent plates were read in CytoFluor
Reader Series 4000 for 40 cycles, for 40 minutes. Cell respiration was determined from
the linear portion of the slope of fluorescence rise. Data are presented as mean ± SEM;
A, P<0.0001 for the variation attributable to oligomycin (two-way ANOVA); B,
P<0.0001; ***P<0.001, **P<0.01.
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7.4. Discussion and conclusion
This chapter is focused on the modulators of superoxide formation in the treated cells.
In particular, we examine the potential mechanisms that lead to the downregulation of
basal ROS in LPON treated cells.
The main findings of this chapter are:
1. LPON was associated with increased AWm
2. Decreased basal ROS observed with LPON was mirrored by a relatively low
mitochondrial NADH/NAD+ ratio. Similarly, enhanced ROS formation
following a further exposure to the energy substrates was paralleled by sustained
rise in mitochondrial NADH/NAD+ ratio.
3. The antioxidant, NAC, lowered the ATm and induced uncoupled respiration in
LPON treated cells.
These findings highlight four important points. First, the relatively low mitochondrial
NADH/NAD+ in LPON treated cells may have been the mechanism underpinning the
unexpected downregulation of basal ROS with LPON. Such a reduction in
mitochondrial NADH/NAD+ ratio can represent either enhanced NADH oxidation or
decreased NADH delivery to the respiratory chain. A prerequisite for enhanced NADH
oxidation is efficient mitochondrial respiration. This is exemplified by the association
between preserved mitochondrial respiration and a relatively low NADH/NAD+ ratio
in oleate treated cells. In effect, active respiration with oleate maintains NADH
oxidation and thereby lowering the NADH/NAD+ ratio. Accordingly, diminished
mitochondrial respiration with LPON is expected to hamper NADH oxidation, thus,
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increasing the NADH/NAD+ ratio. Indeed, mitochondrial NADH/NAD+ ratio with
LPON was higher than that seen in oleate treated cells. However, it was lower than
anticipated; there was no significant difference between LPON and the untreated cells
despite contrasting respiration. This raises the question whether NADH delivery to the
respiratory chain may have been diminished with LPON and whether such reduction
represents a metabolic adaptation gearing to minimize ROS formation.
Second, further exposures to energy substrates can potentially sustain oxidative stress.
In support of this, mitochondrial NADH/NAD+ (and potentially ROS formation) was
increased in LPON pretreated cells after a further 72 hours of treatment. Importantly,
this suggests that a continual substrates exposure can overwhelm any potential
metabolic adaptations that serve to mitigate oxidative stress. This is likely to be an
important mechanism of chronic oxidative stress in dietary-induced steatohepatitis.
Third, the increase in A'/7m with LPON may have reflected a relative or an absolute
decline in ATP formation. The acute rise in respiration, hence active proton extrusion,
may have initially bolstered ATP formation in LPON treated cells. However, the
concomitant oxidative stress can affect the terminal complexes of the respiratory chain
including ATP synthase, thus diminishing ATP formation. Consequently, the proton
reentry into the matrix declines with the resultant rise in A!Fm. In turn, increased AWm
can diminish mitochondrial respiration further. The reduction of AWm by NAC supports
the role of oxidative stress in modulating AWm, the subsequent ROS formation and
mitochondrial respiration.
Finally, another mechanism that may have contributed to lower with NAC is
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enhanced uncoupled respiration. This is a novel finding of this study. It is unknown
whether NAC induces uncoupling proteins that might have led to the rise in uncoupled
respiration. This effect may underlie the lack of improvement in respiration with NAC
in the presence of the uncoupling agent, DNP. Although the uncoupled respiration may
have also played a role in preserving basal and substrate-induced respiration seen with
NAC, the actual contribution would have been modest. It accounted for a mere 5.6% of
the 26% rise in the substrate-induced respiration observed with NAC.
In conclusion, increased energy substrates and the ensuing oxidative stress lead to an
increase in Afm, which in turn, diminishes respiration and promotes ROS formation.
Excessive oxidative stress may have led to adaptations including a reduction in the
mitochondrial NADH/NAD+ ratio to deter a further increase in ROS formation.
However, an ongoing exposure to energy substrate can overcome such adaptations
resulting in chronic oxidative stress.
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8. CHAPTER EIGHT
METABOLIC ADAPTATIONS ASSOCIATED WITH IMPAIRED
MITOCHONDRIAL RESPIRATION
8.1. Introduction
The unanticipated findings of a relatively low mitochondrial NADH/NAD+ with a
concomitant reduction in basal ROS with LPON highlight the importance of
NADH/NAD+ ratio as one of the principal energy sensors. The three main sensors,
NADH/NAD+, ATP/AMP and acetyl-coA, are pivotal for maintaining the intricate
balance between substrate oxidation and ATP formation. Should the substrate
availability exceed the energy demand, these sensors can instigate a cascade of metabolic
adaptations crucial to preserve ATP homeostasis. In this respect, the initial surge of
ROS from substrate oxidation acts as crucial signaling molecules to fine-tune the
subsequent metabolic pathways (43).
Such metabolic adaptation would include modulation of the TCA cycle activity, hence
the NADH delivery to the respiratory chain. Increased energy substrates in hepatic
steatosis is associated with the upregulation of TCA cycle turnover (138). In turn, high
NADH concentration leads to decreased activity of pyruvate dehydrogenase, citrate
synthase, isocitrate dehydrogenase, and a-ketoglutarate dehydrogenase. Decreased
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TCA turnover would divert the superfluous acetyl-coA to non-oxidative pathways
(Figure 8.1).
The impact of impaired mitochondrial function on the TCA cycle in steatohepatitis is
yet to be delineated. It is likely that the concomitant oxidative stress exerts a
considerable influence on the TCA cycle turnover; activities of a-ketoglutarate
dehydrogenase, isocitrate dehydrogenase and succinate dehydrogenase have been shown
to diminish with oxidative stress (139, 140).
In this study, we hypothesized that the observed reduction in mitochondrial
NADF1/NAD+ ratio represents an adaptation to the diminishing mitochondrial
capacity, as well as to the concurrent rise in ROS formation. In a milieu that favours
NADH accumulation such as diminished respiration, such an adaptation would involve
a reduction in the TCA cycle turnover, hence decreasing NADH delivery to the
mitochondrial respiratory chain. Consequently, acetyl-coA is diverted towards the non-
oxidative pathways.
The aims of this chapter are:
1. To determine the association between mitochondrial impairment and TCA cycle
activity in LPON treated cells.
2. To examine the pattern of acetyl-coA partitioning in LPON treated cells.
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Figure 8.1. Acetyl-coA metabolism.
Acetyl-coA is the crossroad of lipid and glucose metabolism. It enters TCA cycle to
generate NADH/FADH2 for ATP formation. It can also be diverted towards
ketogenesis, fatty acid biosynthesis or towards mevalonate pathway culminating in the





The intermediates of the TCA cycle, fatty acid biosynthesis, and mevalonate pathways
were identified using metabolomics profiling as previously described in section 6.2.2.
8.2.2. Ketogenesis
The rate of ketogenesis was determined by measuring the concentrations of (3-
hydroxybutyrate and acetoacetate in cell culture medium immediately after the 72-hour
as described in section 5.2.4. Cellular protein was quantified as described in section
2.2.5. The rate of ketogenesis was expressed as pmol/gram of total protein/hour.
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8.3. Results
8.3.1. The level ofTCA cycle intermediates in treated cells
To investigate whether impaired mitochondrial respiration altered TCA cycle, we
conducted metabolomics profiling of TCA cycle metabolites. Using this approach, four




Figure 8.3.1. Schematic diagram of the TCA cycle.
TCA cycle intermediates identified in the metabolomics profiling are highlighted in red.
Figure 8.3.1.1 Panel A, shows that citrate level was lower in LPON than that seen with
oleate treated cells consistent with a possible reduction in its formation from acetyl-coA
and oxaloacetate. This also suggests decreased acetyl-coA flux into the TCA cycle with
LPON. Moreover, the level of malate (Panel D) was significantly higher in LPON than
the untreated cells. The conversion of oxaloacetate to malate occurs with increased
substrates, hence reducing the availability of oxaloacetate to condense with acetyl-coA.
































Figure 8.3.1.1. The level ofTCA cycle intermediates in treated cells.
A, Citrate; B, Cis-aconitate; C, Succinate and D, Malate. Metabolites corresponded to
TCA cycle intermediates were identified using metabolomics analysis in cells treated
with the specified substrates. Data are presented as mean ± SD; A, Citrate, P=0.001; B,
Cis-aconitate, P=0.16; C, Succinate, P-0.5; D, Malate, P<0.0001; *"P<0.001, **P<0.01,
*P<0.05.
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8.3.2. The diversion of acetyl-coA to non-oxidative pathways
Next, we examined whether altered TCA cycle observed was associated with the
diversion of acetyl-coA towards non-oxidative metabolic pathways, specifically,
ketogenesis, fatty acid biosynthesis, and the mevalonate pathways (Figure 8.1).
8.3.2.1. Ketogenesis is enhanced with LPON
Figure 8.3.2.1 shows higher ketogenesis with LPON than the untreated cells. Co-
treatment of LPON+NAC led to a considerable reduction in ketogenesis by 41% when
compared with LPON alone. It is likely that the preserved respiration and the potential
reduction in ROS with NAC improved the acetyl-coA flux into the oxidative pathway.
8.3.2.2. Increased fatty acid biosynthesis intermediates with LPON
In the presence of energy substrates excess, citrate is shuttled into the cytoplasm to be
reconverted to acetyl-coA, which is subsequently incorporated in fatty acid biosynthesis.
We identified three intermediates for fatty acids biosynthesis using metabolomics study.
Figure 8.3.2.2 shows that the quantity of fatty acid biosynthesis intermediates identified
was higher in LPON compared with untreated cells suggesting increased acetyl-coA
diversion towards fatty acid biosynthesis.
155
**
Figure 8.3.2.1. Ketogenesis in treated cells.
C3A cells were treated for 72 hours. A separate group of cells were simultaneously
treated with LPON and NAC (lOmM). Acetoacetate and (3-hydroxybutyrate
concentrations were measured in the supernatant after 72 hours as detailed in 5.2.4.























Figure 8.3.2.2. Fatty acid biosynthesis intermediates in treated cells.
A, 3-Oxo-tetradecanoic acid; B, 3-Oxo-decanoic acid; C, 3-Oxo-hexadecanoic acid.
Using the metabolomics study, three metabolites corresponded to the fatty acid
biosynthesis intermediates were identified in cells treated with the specified combination
of energy substrates for 72 hours. Data are presented as mean ± SD; A, P<0.0001; B,
P=0.005; C, P=0.02; *~P<0.001, "P<0.01, *P<0.05.
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8.3.2.3. Mevalonate pathways is not increased with LPON
Acetyl-coA can also be channeled towards mevalonate pathways for the synthesis of
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Figure 8.3.2.3. Mevalonate pathways.
Schematic diagram illustrating mevalonate pathway for the synthesis of cholesterol,
steroid hormones, bile acids, and vitamin D3.
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Using metabolomics analysis, the intermediates of mevalonate pathway were identified;
three were intermediates of bile acid synthesis; three were involved in the steroid
hormone synthesis, mevalonic acid (the main precursor for mevalonate pathway) and 7-
dehydrodemosterol (an intermediate for cholesterol biosynthesis). Figure 8.3.2.3.1
demonstrates the level of mevalonic acid and 7-dehydrodesmosterol. Although these
levels were higher with oleate than that seen with LPON, the differences did not reach
statistical significance. In contrast, the level of bile acid intermediates; taurocholate
(Figure 8.3.2.3.2 Panel A), glycodeoxycholate (Figure 8.3.2.3.2 Panel B), glycocholate
(Figure 8.3.2.3.2 Panel C) were significandy elevated with oleate when compared with
LPON or the untreated cells. Similarly, the concentrations of cortol, an intermediate for
steroid hormone biosynthesis (Figure 8.3.2.3.3 Panel A) and vitamin D3 metabolites
(Figure 8.3.2.3.3 Panel B and C) were higher in oleate treated cells when compared with
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Figure 8.3.2.3.1. The concentration of mevalonate pathway intermediates in
treated cells.
A, Mevalonic acid; B, 7-Dehydrodesmosterol. Using metabolomics analysis, metabolites
corresponded to the intermediates in cholesterol biosynthesis, mevalonic acid and 7-
dehydrodesmosterol, were identified in treated cells. Data are presented as mean ± SD;
























Figure 8.3.2.3.2. The concentration of bile acid intermediates in treated cells.
A, Taurocholate; B, Glycodeoxycholate; C, Glychocolate. Using metabolomics analysis,
metabolites corresponded to bile acid intermediates were identified in treated cells. Data





















Figure 8.3.2.3.3. The concentration of steroid and vitamin D3 metabolites in
treated cells.
A, Cortol; B, (5Z,7E)-A-Dinor-(l,2)-(9,10)-diseco-5,7,10(19)-cholestatriene-l,2,25-triol
C, (7E)-(3S,6RS)-3-Hydroxy-6,19-epithio-23,24-dinor-9,10-seco-5(10),7-choladien-22-al
S,S-dioxide. Cortol, an intermediate in steroid hormone biosynthesis, and both vitamin
D3 metabolites were identified in cells treated with energy substrates for 72 hours. Data
are presented as mean ± SD; A, P=0.001; B, P=0.04; C, P=0.0006; ***P<0.001, P<0.01.
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8.4. Discussion and conclusion
In this chapter, we sought to examine whether the observed reduction mitochondrial
NADH/NAD+ ratio represents an adaptation to the diminishing mitochondrial
capacity. We postulated that such an adaptation would involve a reduction in the TCA
cycle turnover; hence decreasing NADH delivery to the respiratory chain as well as
lowering the NADH/NAD+ ratio.
The main findings of this chapter are:
1. Mitochondrial impairment with LPON was associated with altered TCA cycle.
2. Acetyl-coA in LPON treated cells was diverted towards ketogenesis and fatty
acid biosynthesis, but not the mevalonate pathways.
Our data suggest possible decreased TCA cycle turnover in the presence of
mitochondrial impairment. In support of this, the concentration ofmalate was increased
with LPON. It is possible that the surge of energy substrates and the subsequent
mitochondrial impairment with LPON would initially lead to a rise in NADH/NAD+
ratio such that it favours the conversion of oxaloacetate to malate (Figure 8.4). The
lowering of oxaloacetate can dampen the TCA cycle turnover, thus diminishing the
subsequent NADH formation (141). In effect, such reduction in oxaloacetate decreases
its availability to condense with acetyl-coA to form citrate. Indeed, citrate levels were
lower with LPON compared with oleate. Furthermore, citrate synthase activity is
diminished in the presence of oxidative stress as well as in elevated NADH/NAD+ (98,
142).
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The diversion of acetyl-coA towards ketogenesis is yet another classic acute metabolic
adaptation to the reduction in TCA cycle activity. Acetyl-coA is also diverted towards
free fatty acid synthesis with LPON. However, it is likely that acetyl-coA diversion is
influenced by cell demand and ATP availability. For example, acetyl-coA did not appear
to be diverted towards the mevalonate pathways with LPON. Indeed, in the absence of
ATP formation, for example in mitochondrial dysfunction, mevalonate pathways are
down regulated.
These adaptations are necessary in the presence ofmitochondrial impairment. Excessive
supply of NADH in the presence of electron flow disruption (for example, in ROS-
induced mitochondrial injury) can promote further ROS formation. Thus, these
















Figure 8.4. Metabolic adaptations instigated by the rise in energy substrates.
Increased energy substrates availability initially enhanced NADH/NAD+ ratio with
resultant rise in mitochondrial ROS formation. This would eventually decrease citrate
synthase activity as well as favouring the conversion of oxaloacetate to malate, thus
slowing down the TCA cycle turnover. The reduction in the TCA cycle leads to two
important consequences. First, NADF1 formation declines, lowering the NADF1/NAD+




THE RELATIONSHIP BETWEEN TRIGLYCERIDE ACCUMULATION,
REACTIVE OXYGEN SPECIES, MITOCHONDRIAL FUNCTION AND
GLUCOSE METABOLISM
9.1. Introduction
The association between insulin resistance and hepatic steatosis is well established.
Hepatic triglyceride content has been shown to correlate with hepatic insulin resistance,
and reducing hepatic steatosis either pharmacologically or through dietary modification
leads to significant improvements in hepatic insulin resistance in humans (89, 90, 143-
145). In rodents, manipulation of enzymes involved in triglyceride synthesis to reduce
liver fat has been shown to enhance insulin sensitivity.
However, the molecular details that underlie this association remain to be elucidated.
Furthermore, there is emerging evidence that supports the dissociation between insulin
resistance and hepatic triglyceride accumulation. It is unclear if triglyceride
accumulation per se mediates insulin resistance or whether it hinges on concurrent
factors, notably oxidative stress.
The presence of mitochondrial impairment is adding to the complexity of this
relationship. Although mitochondrial function is strongly associated with insulin
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resistance, the causal relationship remains unclear; is mitochondrial dysfunction a cause
or a consequence, or simply a parallel event to the development of insulin resistance?
Importantly, the question remains whether altered glucose metabolism represents a
metabolic adaptation to prevent mitochondrial overload in the presence of increased
energy substrates and mitochondrial impairment.
The aims of this chapter are:
1. To examine gluconeogenic capacity in the treated cells, and determine the
contribution of triglyceride and ROS in gluconeogenesis.
2. To determine the effect of LPON on factors that can modulate endogenous glucose
formation specifically glycolysis and glycogen turnover.
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9.2. Methods
9.2.1. Glucose and acyl carnitine concentrations
These were identified using the metabolomics approach as described in 6.2.2.
9.2.2. Gluconeogenic capacity
Gluconeogenic capacity was determined by measuring glucose flux following a 4-hour
incubation with LPON. Culture supernatant was removed and cells were rinsed with
PBS. LPON was then added to all groups. Glucose concentration in the incubation
medium was determined at the end of the incubation using Bergmeyer's enzymatic
methods (129). Briefly, glucose concentration corresponds to the NADH produced
from the following reactions:
Glucose+ATP Hexokinase ^ Glucose 6-phosphate
Glucose 6-phosphatc
Glucose 6-phosphate+NAD+ ———-► Gluconolactone 6-phosphate+NADH
The assay was prepared using: NAD+ (0.34mg/ml), ATP (2.5txl/ml), glucose 6-
phosphate dehydrogenase (0.25p]/ml), hexokinase (0.5pl/ml) in PBS. The assay (1ml)
was added to the supernatant of treated cells (200pl), homogenized and analysed using
spectrophotometer (340nm). The concentration was averaged for total protein to obtain
pmol. gram of total protein '.hour1 as described in section 2.1.5.
9.2.3. The effect of insulin on treated cells
Cells were grown and treated with LPON in 6-well plates as previously described. After
72 hours, the supernatant was removed and cells were rinsed. The culture media were
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replaced with MEME without FBS for 24 hours. Cells were then rinsed before a 4-hour
incubation with insulin at the specified concentrations determined from a dose-response
curve (Supplementary Data 2). Glucose flux in the incubation medium was determined
as described in section 9.2.2. Lactate and pyruvate concentrations were determined as
described in section 6.2.2.
Glycogen is the main source of endogenous glucose formation in the absence of
gluconeogenic substrate. Glycogen breakdown results in the formation of glucose 6-
phosphate, which can either enter glycolysis or subject to glucose 6-phosphatase to
produce glucose (Figure 9.2.3). Thus, the final concentrations of lactate, pyruvate, and
glucose (2x(glucose)+lactate+pyruvate) reflect the total flux through glucose 6-
phosphate. Similarly, the percentage of glycogen diverted to glucose or glycolysis can be
calculated as follows:
Percentage of glycogen diverted to glucose:
(2 x (glucose) / (2 x (glucose))+lactate+pyruvate) x 100
Percentage of glycogen diverted to glycolysis:






















Figure 9.2.3. Flux through glucose 6-phosphate.
Glycogen breakdown results in the formation of glucose 6-phosphate, which can enter
the glycolytic pathway (purple arrows) or can be converted to glucose by glucose 6-
phosphatase (pink arrow). Thus, the overall flux through glucose 6-phosphate can be
determined from the concentrations of glucose, lactate and pyruvate. The percentage of
glycogen diverted to glucose and glycolytic pathway can be measured as described
above.
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9.2.4. Glycogen detection using Periodic Acid Schiff (PAS) Staining
Cells were grown and treated in two-chamber slides until 70% confluent. Cells were
fixed in 10% formaldehyde. Mr. Robert Morris from Queen's Medical Research
Institute kindly performed the PAS staining. Briefly, slides were rehydrated and oxidized
in 0.5% periodic acid solution for 5 minutes. Slides were then rinsed in distilled water,
placed in Schiff reagent for 15 minutes, rinsed in warm water for 5 minutes and
counterstained in hematoxylin before mounting. Images were viewed under light
microscopy. At least three different slides from each group were analysed using ImageJ.
A threshold for each image was set to highlight the stained area. Using 'analyze particle'
function, the extent of the stained area was quantified and data are expressed in pixel.
9.2.5. Lipid droplets surface area to volume ratio
Cells were cultured on a chamber slide and treated for 72 hours before being stained
using BODIPY 493/503 as described in section 3.2.3. To determine the lipid droplets
surface area to volume ratio, the stack of 3D BODIPY confocal images were analysed
using Volocity 3D image analysis software (Perkin Elmer, Waltham, MA, USA).
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9.3. Results
9.3.1. Glucose formation is enhanced in LPON treated cells
Having confirmed the presence of insulin receptors in treated C3A cells (Supplementary
data 1.1), we then focused on the impact of LPON on glucose metabolism. In the
presence of energy substrate excess, acetyl-coA exerts a negative feedback on pyruvate
dehydrogenase (PDH) thus allowing lipid oxidation to take precedence over that of
glucose. Using metabolomics, peaks that corresponded to D-glucose were identified at
the end of the treatment. As shown in Figure 9.3.1, glucose concentration was higher in
LPON than that seen with the untreated cells. In contrast, the concentration of glucose
with oleate was similar to the untreated cells.
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Figure 9.3.1. Glucose concentration in treated cells.
Using the metabolomics technique as described in 9.2.1, peak that corresponded to D-
glucose was identified. Cells were treated for 72 hours. Data are presented as mean ±
SD; P<0.0001; ***P<0.001.
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9.3.2. Gluconeogenic capacity is enhanced in LPON treated cells
To investigate whether increased glucose formation with LPON is attributable to
enhanced gluconeogenic capacity, LPON were added to all groups as described in
section 9.2.2. Figure 9.3.2 represents glucose concentrations at the end of a 4-hour
incubation with LPON. Glucose concentration with LPON was significantly higher
than that seen with oleate or the untreated cells consistent with enhanced gluconeogenic
capacity in these cells. Importantly, concomitant treatment with NAC resulted in a 43%
reduction in glucose formation in the LPON treated cells suggesting the role of ROS in
promoting gluconeogenesis. Interestingly, cells treated with octanoate alone had higher
gluconeogenic capacity than that seen with oleate treated cells.
9.3.3. Glycolysis is diminished in LPON treated cells
Next, we examined whether enhanced glucose formation with LPON was associated
with decreased glycolysis. Glycolysis was determined by measuring lactate and pyruvate
concentrations following a 4-hour incubation with glucose (20mM). Figure 9.3.3
demonstrates lower glycolysis with LPON than the untreated cells. Furthermore, despite




Figure 9.3.2. Gluconeogenic capacity in treated cells.
Glucose flux was determined at the end of a 4-hour incubation period as described in
section 9.2.2. Data presented are presented as mean ± SEM; P<0.0001; ***P<0.001,
*P<0.05. LPON+NAC; LPON+N-acetylcysteine.
Figure 9.3.3. Glycolysis flux in treated cells.
Culture supernatants from treated cells were replaced with MEME (without FBS) for 24
hours. Cells were then rinsed and incubated in glucose (20mM) in the presence of
octanoate (4mM) for 4 hours. Lactate and pyruvate concentrations were measured
(section 5.2.4). Data are presented as mean ± SEM; P<0.0001; **P<0.01, *P<0.05.
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9.3.4. Glycogen accumulation is reduced with LPON treated cells
We examined the contribution of glycogen turnover towards endogenous glucose
formation with LPON. First, we examined whether LPON altered the amount of
glycogen accrued in C3A cells. PAS staining was performed and quantified using ImageJ
as described in section 9.2.4. Panel A of Figure 9.3.4 shows that glycogen was rendered
bright magenta with PAS staining. Panel B and C are representative images of PAS
stained untreated and LP cells respectively. Panel D demonstrates a PAS stained image
set to a threshold using ImageJ to highlight the magenta area of glycogen accumulation.
Panel E and F represent PAS stained images of LPON and octanoate treated cells.
LPON and octanoate treated cells have visibly less magenta areas than that seen with
LP and untreated cells. Indeed, quantification using ImageJ confirmed that glycogen
accumulation in LPON was lower than the untreated cells (Panel G).
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Figure 9.3.4. Glycogen accumulation in treated cells.
A, PAS stained area (indicated by the arrow) in untreated cells viewed under light
microscopy (magnification xlO); B, PAS stained (white arrow) untreated; C, LP treated
cells (magnification x4); D, PAS stained area in LP treated cells highlighted by Image J;
E and F, PAS stained LPON and octanoate treated cells respectively; G, Stained area
quantified by Image J. PAS staining was performed as described in section 9.2.4. Data
are presented as mean ± SEM; P-0.02; *P<0.05.
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9.3.5. Increased glycogen turnover with LPON treated cells
We then determined whether reduced glycogen accumulation with LPON could be
attributable to increased glycogen turnover. Additionally, we examined whether the
breakdown of glycogen with LPON is partitioned towards glucose formation rather
than glycolysis. Glycogen breakdown produces glucose 1-phosphate, which is then
converted to glucose 6-phosphate. Glucose 6-phosphate can enter glycolysis producing
lactate and pyruvate, or dephosphorylated to form glucose (Figure 9.2.3). Insulin is
expected to promote glycolysis and reduce glucose formation. Therefore, we compared
the effect of insulin on glucose formation from glycogen in LPON and oleate treated
cells. The concentration of insulin used (0-15mM) was determined from a dose
response curve (Supplementary data 1.2).
Figure 9.3.5 Panel A shows that the overall flux through glucose 6-phosphatase was
significantly higher in LPON than the untreated cells. The presence of insulin (0-15nM)
did not alter the overall flux in LPON or the untreated cells. There was a non-statistical
significant trend of reduced flux through glucose 6-phosphate with insulin (5nM) in
oleate treated cells. In contrast, the percentage of glycogen diverted to glucose was
significantly lowered by insulin (5nM) in oleate treated cells. This remained unaltered in
LPON and the untreated cells (Panel B). Panel C shows the diversion towards
glycolysis. The pattern was diametrical to that seen in glucose formation. There was a
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Figure 9.3.5. The effect of insulin on glycogen turnover in treated cells.
A, The overall flux through glucose 6-phosphate; B, The percentage of glycogen
diverted towards glucose formation; C, The percentage of glycogen diverted towards
glycolysis. Panel A-C, treated cells were incubated with insulin at the specified
concentrations. The percentage of glycogen diverted to glucose and glycolysis was
calculated as previously described in section 9.2.3. A, P<0.0001 for the overall effect of
treatment. ***P<0.001, *P<0.05 when compared to the corresponding untreated cells. B,
The effect of treatment was significant (P=0.005) whilst the effect of insulin on the
untreated and LPON cells was not statistically significant (P=0.07). *P<0.05 between 0
and 5nM of insulin in oleate treated cells. C, The effect of treatment was significant
(P=0.01) whilst the variation due to insulin did not reach statistical significance (P—0.3).
Data are presented as mean ± SEM.
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9.3.6. Triglyceride reduction with metformin does not lower glucose formation
Next, we examined whether the reduction in triglyceride accumulation induced by
metformin would lower glucose concentration in LPON cells. A separate group of cells
were treated with LPON and metformin (50nM and ImM) for 72 hours. We have
previously shown that metformin (ImM) reduced triglyceride accumulation in LPON
treated cells (Figure 5.3.3.2). The concentration of glucose in the supernatant was
measured as described in section 9.2.2. As shown in Figure 9.3.6, metformin did not
alter glucose concentration in LPON treated cells.
180
LP0N+Metformin
Figure 9.3.6. The effect ofmetformin on glucose formation in treated cells.
Cells were treated for 72 hours in six-well plates. Separate group of cells were treated
with LPON and metformin at the concentration specified. Glucose concentrations in
the culture supernatant were measured as described in section 9.2.2. Data are presented
as mean ± SD; P<0.0001; ~*P<0.001, **P<0.01.
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9.3.7. Other factors that may have influenced glucose metabolism
The disparity in glucose metabolism between LPON and oleate treated cells suggests
that the extent of triglyceride accumulation does not influence glucose metabolism.
Furthermore, the reduction in triglyceride accumulation with LPON+metformin did
not lower glucose formation. Therefore, we examined two factors that have been
proposed to influence insulin sensitivity-the surface area to volume ratio of the lipid
droplets and acyl-carnitine concentration.
9.3.7.1. Lipid droplets surface area to volume ratio
Recent evidence suggests that increased surface area to volume ratio enhances insulin
sensitivity (146). Conversely, reduced surface ratio to volume as often found with larger
droplets is thought to limit the access of lipases leading to incomplete triglyceride
hydrolysis. This can result in the formation of DAG, which in turn, can potentially
impede insulin signaling through the activation of PKCe. Using 3D image analysis
software, we determined the surface area to volume ratio in treated cells. Figure 9.3.7.1
demonstrates that surface area to volume ratio was significantly higher in the untreated
and oleate treated cells when compared with LPON cells after 72 hours.
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Figure 9.3.7.1. The surface area to volume ratio of lipid droplets accumulated.
Cells were grown in two-chamber slides and treated for 72 hours. The surface area and
volume were determined using 3D software, Volocity. Data are presented as mean ±
SD; PC0.0001; "*P<0.001, **P<0.01.
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9.3.7.2. Acyl-carnitine concentrations were higher in LPON treated cells.
Peroxisomal fPoxidation of the long chain fatty acids results in shorter fatty acid chains,
which are converted to acyl carnitines. Acyl carnitines, subsequently, enter the
mitochondria to undergo complete ^-oxidation. Increased concentration of even-chain
acyl carnitine (C4-C22) reflects decreased/overwhelmed mitochondrial ^-oxidation.
Raised even-chain acyl carnitine concentrations have been observed in individuals with
Type 2 diabetes and has been associated with impaired fatty acid oxidation in animal
models of obesity (147, 148). Increased even-chain species of acyl carnitine
concentrations is thought to contribute towards insulin resistance by activating NFkB
pathways (149).
Using metabolomics, we identified metabolites that corresponded to acyl carnitines in
the treated cells. Figure 9.3.7.2.1 demonstrates increased butanoylcarnitine (C4),
hexanoylcarnitine (C6) and octanoylcarnitine (C8) concentrations with LPON when
compared with oleate and the untreated cells. In contrast, the odd-chain acyl carnitine;
propanoylcarnitine (C3), tiglylcarnitine (C5) and heptanoylcarnitine (C7) concentrations
were lower with LPON than oleate or the untreated cells (Figure 9.3.7.2.2). These




Figure 9.3.7.2.1. Even-chain acyl carnitine concentration in treated cells.
A, Butanoylcarnitine (C4), (P<0.0001); B, Hydroxybutyrylcarnitine (C4), (P<0.0001); C,
Hexanoylcamitine (C6), (P<0.0001); D, Octanoylcarnitine (C8), (P<0.0001); E,
Decanoylcarnitine (CIO), (P=0.45). The concentrations of acyl carnitine were
determined using metabolomics in cells that have been treated for 72 hours. Data are



















































































9.4. Discussion and conclusion
In this chapter, we dissect the relationship between glucose metabolism, triglyceride
accumulation and mitochondrial function. Our data highlight several important points.
First, the extent of triglyceride accumulation does not influence glucose metabolism.
Despite the similarity in triglyceride accumulation, LPON, not oleate, had enhanced
glucose formation paralleled by increased gluconeogenic capacity, decreased glycolysis,
reduced glycogen accumulation and enhanced glycogen turnover. Similarly, triglyceride
reduction does not necessarily affect glucose formation. Diminished triglyceride
accumulation in cells concomitantly treated with LPON and metformin was not
mirrored by a reduction in glucose formation.
The next question is whether altered glucose metabolism observed with LPON is driven
by ROS. Indeed, ROS have been proposed to alter insulin signaling (92). The reduction
in gluconeogenesis with NAC corroborates the role of ROS in altering glucose
metabolism in LPON treated cells. However, increased gluconeogenesis and reduced
glycogen accumulation occurred in octanoate treated cells without a discernible rise in
ROS formation. In this respect, it is likely that accelerated acetyl-coA formation with
octanoate (as evidenced by enhanced ketogenesis) inhibits pyruvate dehydrogenase
(PDH), thus diverting pyruvate towards the gluconeogenic pathways. The presence of
ROS can augment this further. Decreased TCA cycle activity with concomitant
mitochondrial dysfunction in the presence of oxidative stress can augment acetyl-coA
accumulation. In contrast, NAC promotes acetyl-coA flux into the TCA cycle, which is
likely to underpin its ability to reduced gluconeogenic capacity (150).
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Second, the importance of acetyl-coA in glucose metabolism also underlies the
observation that impaired glucose tolerance precedes mitochondrial impairment (98).
Increased gluconeogenic capacity with octanoate occurs in the presence of preserved
mitochondrial function.
Third, abnormal glucose metabolism is associated with the dysregulation of fatty acid
metabolism. Enhanced formation of acetyl-coA with LPON promotes de novo
lipogenesis with resultant long chain fatty acids formation. Enhanced oo- and
peroxisomal (3-oxidation of long chain fatty acids yields a significant amount of fatty
acid intermediates that rely on the mitochondria for complete oxidation. Thus,
mitochondrial (3-oxidation is overwhelmed as evidenced by higher acyl carnitine
concentrations. Similarly, decreased surface area to volume of lipid droplets can result in
incomplete triglyceride hydrolysis leading to the formation of DAG in LPON treated
cells. Both acyl carnitine and DAG have been implicated in the pathogenesis of insulin
resistance (149, 151).
In summary, the formation of acetyl-coA, rather than cellular steatosis per se, is an
important determinant to glucose dysregulation. Conditions that accelerate acetyl-coA
accumulation, for example, an ongoing surge of energy substrate or ROS-induced TCA
cycle downregulation is likely to augment this effect further.
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Figure 9.4. The effect of LPON on gluconeogenesis.
The rise in mitochondrial NADH/NAD+ ratio and increased oxidative stress reduce the
TCA cycle turnover. Consequently, the acetyl-coA flux into the cycle is decreased. This
results in acetyl-coA accumulation, which instigates the pyruvate dehydrogenase to
inhibit the conversion of pyruvate to acetyl-coA. As a result, pyruvate is carboxylated to
form oxaloacetate. Oxaloactetate is converted to malate and transported out of the
mitochondria to form phosphoenoylpyruvate. Phosphoenoylpyruvate enters the
gluconeogenic pathway culminating in the production of glucose. The impact of acetyl-
coA per se occurs even before the onset of mitochondrial dysfunction. However, the
onset of mitochondrial dysfunction enhances acetyl-coA accumulation thus amplifying
these events. Additionally, increased ROS formation with mitochondrial dysfunction




Our study sought to dissect the relationship between fat accumulation, reactive oxygen
species and mitochondrial function in NAFLD. Understanding this relationship is a
critical question since a considerable proportion of individuals with steatosis progress to
steatohepatitis. To address this fundamental question, we have designed in vitro models
of cellular steatosis using various combinations of physiological energy substrates that
are relevant to human dietary nonalcoholic fatty liver disease.
In vitro model ofcellular steatosis
The prerequisite of substrate chosen is its ability to induce adequate steatosis in addition
to its capacity in promoting tricarboxylic acid cycle (TCA) activity to generate NADH
for mitochondrial respiratory chain. We have shown that treatment with oleate or
octanoate induced significant triglyceride accumulation in C3A cells. The addition of
energy substrates, lactate and pyruvate, to octanoate enhanced the triglyceride
accumulation, supporting the hypothesis that these substrates synergized to promote de
novo lipogenesis. Increased fatty acid biosynthesis intermediates, enhanced concentration
of acyl carnitines and increased dicarboxylic acid formation corroborate the presence of
augmented de novo lipogenesis with LPON.
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As evidenced by the differences in their mitochondrial respiration, fatty acids oleate or
octanoate, with or without the combination of gluconeogenic substrates (lactate and
pyruvate), and/or ammonia acutely modulated the TCA cycle turnover. We have shown
that lactate, pyruvate, octanoate and ammonia synergized to enhance acute respiration
and ROS formation to a critical point, culminating in mitochondrial impairment.
Indeed, LPON-induced cellular steatosis manifests many of the key features associated
with steatohepatitis such as impaired mitochondrial function, enhanced oxidative stress,
increased ketogenesis and altered glucose metabolism. In stark contrast, triglyceride
accumulation with oleate represents simple steatosis; mitochondrial function remained
unperturbed despite the triglyceride accrued.
The focus was then to observe the events that occur as consequences of enhanced TCA
activity similar to what potentially may occur with nutrient excess. Our aims were to
determine (i) whether steatosis per se affects mitochondrial respiration and (ii) whether
its effects are essentially hinged on ROS formation.
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Cellular steatosisper se does not influence mitochondrialfunction
Our data have several important implications for understanding the events surrounding
mitochondrial dysfunction in nutrient perturbation. First, cellular steatosis per se does
not influence mitochondrial function. In support of this, mitochondrial function was
significantly different between oleate and LPON despite their similarities in triglyceride
accumulation. Enhanced respiration with LPON was not sustained; evidence of
mitochondrial impairment was apparent after 72 hours as supported by decreased basal
and substrate-driven respiration as well as diminished mitochondrial chain capacity.
Likewise, mitochondrial function remained unaltered with LPO despite higher
intracellular triglyceride accumulation than LPON. There are two potential mechanisms
behind the lower triglyceride content with LPON when compared with LPO treated
cells. First, impaired mitochondrial function would lead to ATP depletion, thus
switching off ATP-consuming processes including de novo lipogenesis. Indeed,
downregulation of lipogenic enzymes has been proposed to be the mechanism of
decreased steatosis or 'burnt out' appearances in advanced NASH (34). Second, as
discussed previously, ammonia has been shown in astrocytes to decrease the formation
of triglycerides with concomitant rise in diacylglycerides further supporting the
importance of triglycerides in protecting cells from the potential deleterious effect of
free fatty acids (108, 121).
Importantly, reduction in intracellular triglyceride as observed with LPON in the
presence of metformin, does not necessarily lead to an improvement in mitochondrial
function. Mitochondrial respiration was significantly depressed with metformin despite
a significant reduction in lipid accumulation. Moreover, the dose-dependent reduction
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in triglyceride with metformin was paralleled by increased mitochondrial and cytosolic
NADH/NAD+ ratio suggesting decreased NADH oxidation. Such mitochondrial
impairment can lead to a decline in ATP formation leading to a rise in AMP to ATP
ratio. Indeed, metformin has been shown to lower triglyceride content by activating
AMP-activated protein kinase (AMPK), a sensor of cellular energy activated by ATP
depletion and is responsible for limiting ATP utilization (127, 128). Furthermore,
significant mitochondrial impairment with metformin would lead to a decline in (3-
oxidation. Functioning mitochondrial respiration is a prerequisite to sustaining |3-
oxidation (152). Consequently, acetyl-coA formation for de novo lipogenesis would
diminish.
ROS, not triglyceride accumulation, is a key determinant ofmitochondrialfunction
Second, our data underline the importance of energy substrates capacity to form ROS,
rather than their ability to induce triglyceride accumulation, as a key determinant of
mitochondrial function. We have shown that LPON acutely enhanced ROS formation
culminating in increased mitochondrial membrane potential and diminished
mitochondrial respiration. The addition of antioxidant NAC reduced the mitochondrial
membrane potential and prevented the decrease in basal and substrate-induced
respiration seen in LPON-treated cells, thus supporting the role of ROS in modulating
mitochondrial function in nutrient perturbation (43, 153). Taken together, these results
indicate an inhibition of oxidative phosphorylation mediated by ROS possibly on the
terminal components of mitochondrial respiratory chain, cytochrome c oxidase
(complex IV). ROS and high fat diet have been previously shown to diminish
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cytochrome c oxidase activity leading to an increase in NADH/NAD+ and high
mitochondrial membrane potential (142, 154). Therefore, it is plausible that the
enhanced ROS is responsible for the ensemble of mitochondrial effects observed with
LPON.
Akin to the findings in steatohepatitis, ROS formation in LPON-treated cells was not
mitigated by diminished respiration (40, 59). Although the endogenous (basal) ROS
formation between LPON and oleate was similar, the capacity to form ROS was higher
with LPON. Indeed, there was a dramatic rise in superoxide formation with further
LPON. The renewed NADH supply from the additional energy substrates are likely to
burden the already strained oxidative phosphorylation leading to the rise in
NADH/NAD+ ratio as well as increased membrane potential (123, 155). In contrast,
treatment with oleate did not affect cell respiration and maintained a relatively low
mitochondrial membrane potential, resulting in a smaller amount of superoxide
formation. Additionally, the intact respiration maintains constant NADH oxidation thus
further minimizing the ROS formation (156).
Despite the downregulation of basal ROS formation after 72 hours, the presence of
oxidative stress is apparent with LPON as evidenced by increased lipid peroxidation,
enhanced dicarboxylic acid formation and elevated isoprostane levels. Furthermore,
similar to that seen with FFA overload in obesity and diabetes, the formation of short
and medium chain dicarboxylic acids from co-oxidation can overwhelm (3-oxidation.
Additionally, dicarboxylic acids can promote mitochondrial impairment through three
potential mechanisms. First, they inhibit mitochondrial respiration (133). Second, their
futile recycling across the mitochondrial membrane can result in proton dissipation and
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uncoupling respiration (157). Third, the oo-oxidation that leads to their formation and
their oxidation by the peroxisomal (3-oxidation can generate a substantial amount of
ROS (158).
The potential explanation for the similarities in basal ROS formation between LPON
and the untreated cells is that the mitochondrial NADH/NAD+ ratio was comparable
between the two groups. However, preserved mitochondrial function in the untreated
cells, as evidenced by active respiration and low mitochondrial membrane potential, is
likely to maintain steady flow of electrons along the mitochondrial chain necessary for
an efficient NADH oxidation to NAD+. The findings of lower cytosolic NADH/NAD+
ratio in the untreated cells compared with LPON further support this notion.
Therefore, it is plausible that the similarity in mitochondrial NADH/NAD+ ratio
reflects the differences in the rate of NADH formation from the TCA cycle.
Specifically, the 72-hour LPON treatment may have led to the downregulation of TCA
cycle and the observed mitochondrial NADH/NAD+ ratio may have been normalized
as part of the ensuing metabolic adaptations to limit ROS production.
In support of this, the concentration of malate, a TCA cycle intermediate, was found to
be significantly higher with LPON than either oleate or the untreated cells. It is possible
that the surge of energy substrates and the subsequent mitochondrial impairment with
LPON would initially lead to a rise in NADH/NAD+ ratio such that it favors the
conversion of oxaloacetate to malate. The lowering of oxaloacetate can dampen the
TCA cycle turnover, thus diminishing the NADH formation (141). In effect, such
reduction in oxaloacetate decreases its availability to condense with acetyl-coA to form
citrate. Indeed, citrate levels were lower with LPON compared with oleate.
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Furthermore, citrate synthase activity is diminished in the presence of oxidative stress as
well as in elevated NADH/NAD+ (98, 142). Although it is conceivable that reduced
basal respiration observed with LPON reflects decreased NADH availability, it is
unlikely that this underpins the diminished substrate-induced respiration, particularly in
the presence ofDNP.
These adaptations are necessary in the presence ofmitochondrial impairment. Excessive
supply of NADH in the presence of electron flow disruption (for example, in ROS-
induced mitochondrial injury) can promote further ROS formation. This is supported
by the dramatic rise in ROS formation in LPON treated cells with further substrates.
Importantly, it is likely that an ongoing surge of energy substrates can overcome the
initial metabolic adaptations and their effects can be persistent. Indeed, mitochondrial
NADH to NAD+ ratio remained increased in LPON treated cells even after a further 72
hours of treatment. These conditions would favour ROS formation and thus, could
potentially sustain the ROS formation leading to chronic oxidative stress.
The presence of oxidative stress with LPON is associated with several metabolic
derangements. It is likely that these derangements represents adaptations to ROS
mediated mitochondrial impairment. The diversion of acetyl-coA towards ketogenesis is
a classic example of an acute metabolic adaptation to the reduction in the TCA cycle
turnover. Indeed, steatohepatitis is characterized by enhanced ketogenesis without
concomitant rise in jl-oxidation (32). In the presence of decreased TCA cycle activity,
acetyl-coA can also be diverted towards de novo lipogenesis and/or mevalonate pathways,
depending on the ATP supply and cell demand. The findings of enhanced de novo
lipogenesis with LPON and increased mevalonate pathways with oleate are likely to
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reflect the discrepancy in ATP formation; mitochondrial impairment in LPON can
potentially lead to decreased ATP formation. A relatively high mitochondrial membrane
potential and increased uncoupled respiration observed with LPON support less ATP
formation in these cells. Although de novo lipogenesis is an ATP consuming process, it is
likely that protecting cells against the deleterious effect of free fatty acids supersedes the
need for mevalonate pathways in LPON treated cells.
Increased gluconeogenesis exemplifies another appropriate response to curb further
ROS formation from excessive substrate flux into the TCA cycle. In the setting of
nutrient excess, increased mitochondrial superoxide production has been proposed to
be the signal that drives a cellular response to induce insulin resistance as part of the
antioxidant defense mechanism (159). Enhanced gluconeogenic capacity with LPON
was paralleled by diminished glycolysis, increased glycogen turnover and enhanced
partitioning of glycogen towards glucose formation. Taken together, these findings are
consistent with decreased insulin sensitivity. In contrast, endogenous glucose formation
is diminished with oleate consistent with preserved insulin sensitivity (85, 107).
Importantly, the contrasting glucose metabolism between LPON and oleate highlights
the discrepancy between triglyceride accumulation and glucose formation.
The finding of enhanced gluconeogenic capacity in octanoate and LPO-treated cells
suggests that altered glucose metabolism occurs before the onset of mitochondrial
impairment. In this respect, increased acetyl-coA formation that occurs before the onset
of mitochondrial impairment is likely to contribute to enhanced glucose formation.
There are two potential mechanisms that underlie the association between acetyl-coA
and gluconeogenesis. First, increased acetyl-coA inhibits pyruvate dehydrogenase thus
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diverting pyruvate towards gluconeogenesis. Second, acetyl-coA can be diverted towards
de novo fatty acid synthesis resulting in long chain fatty acids formation. Incomplete long
chain fatty acid oxidation yields acyl carnitine species, which have been implicated in the
pathogenesis of insulin resistance.
The importance of acetyl-coA in determining glucose formation is further highlighted
by the effect of NAC on glucose formation. The concomitant reduction in ketogenesis
observed with NAC suggests reduced acetyl-coA accumulation, which is likely to be
attributable to increased acetyl-coA flux into the TCA cycle. Indeed, NAC has been
shown to improve TCA cycle metabolism by augmenting the carbon flux through PDH,
independent of its ability to replenish glutathione stores (150). Importantly, the
reduction in mitochondrial membrane potential with NAC can potentially decrease ROS
formation and promote insulin sensitivity.
The finding that mitochondrial alterations do not precede insulin resistance is consistent
with a previous study (98). However, the onset of mitochondrial impairment can sustain
insulin resistance through two potential mechanisms. First, mitochondrial impairment
augments ROS formation, which in turn, can alter insulin-signaling molecules (92).
Second, an increase in NADH/NAD+ ratio with mitochondrial impairment can lead to
metabolic adaptations including a reduction in TCA cycle turnover with concomitant
rise in gluconeogenesis. Such effects on glucose formation would continue until a
decline in ATP formation reached a critical point culminating in the activation of
AMPK pathways. AMPK reduces gluconeogenesis in an attempt to limit ATP
consumption (160). In addition, the activation of AMPK-F0X03 pathway has been
shown to reduce ROS thus preserving insulin-signaling activity (161).
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It is likely that the alteration in glucose metabolism driven by the excessive acetyl-coA
parallels, if not precedes, any impairment in insulin signaling. In fact, altered insulin-
signaling heralds the possibility of significant mitochondrial impairment and excessive
ROS formation. In this respect, impaired insulin signaling can confer a protective but
limited effect by reducing glucose oxidation and resultant ROS formation. Thus, the
aberration of insulin signaling parallels or represents a consequence of mitochondrial
impairment whereas altered glucose metabolism, as previously discussed, occurs before
the onset of discernible mitochondrial impairment.
Another factor that can influence glucose formation in these cells is the differences in
the surface area to volume ratio of the lipid droplets. The higher surface area with
smaller lipid droplets allows complete action of lipase. Conversely, a reduction in the
surface area with larger droplets can lead to partial triglyceride hydrolysis resulting in the
development of diacylglycerol formation (162). The surface area to volume of lipid
droplets was significandy reduced with LPON. Indeed, dietary-induced NAFLD is
characterized by predominandy macrovesicular steatosis. Factors that lead to the
formation of larger lipid droplets and macrovesicular steatosis remain to be elucidated.
Similar to that seen with steatohepatitis, mitochondrial impairment with LPON was
associated with altered mitochondrial structure. Elongated mitochondria with indistinct
cristae akin to that described in steatohepatitis were more frequently observed with
LPON (64). Such morphological changes in steatohepatitis have been associated with
increased hepatic oxidative stress (32, 40). Indeed, ROS have been implicated in the
development of megamitochondria, which as the name implies, are characterized by
enlarged mitochondria, often unusual in shape, with pale matrix and devoid of cristae
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(82). However, there was a decrease in the overall cross-sectional area of the
mitochondria in LPON cells. Mitochondria are dynamic organelles capable of
undergoing constant fusion and fission in response to the ever-changing ROS
concentration (60, 84). Smaller mitochondria are thought to represent ongoing
fragmentation reported to occur transiendy in the presence of ROS. Subsequent
increased in fusion can result in enlarged and elongated mitochondria thereby
decreasing the overall surface area to limit the release ofROS (84).
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Figure 10.1. The consequences of increased energy substrates in the liver.
Schematic diagram to illustrate the sequence of events that can occur following an
exposure to energy substrates. The rise in energy substrates increases respiration and
enhances ROS formation. In turn, ROS lead to mitochondrial impairment. The onset of
mitochondrial impairment instigates metabolic changes gearing to preserve ATP
formation and to curtail further mitochondrial ROS formation (grey arrows). Such
adaptations would include decreased TCA cycle activity, which can promote the
partitioning of acetyl-coA to non-oxidative pathways including the de novo lipogenesis
pathway. Increased ROS enhances lipid peroxidation producing intermediates that can
overwhelm mitochondrial (3-oxidation and activate alternative fatty acid oxidation
pathways. These pathways generate further ROS as well as reactive lipid species thought
to be responsible for lipotoxicity. MRC, mitochondrial respiratory chain; ROS, reactive
oxygen species; FFA, free fatty acid; TCA, tricarboxylic acid cycle; LCFA, long chain
fatty acids.
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Metabolic effect ofNAC in hepatocytes
Third, our data provide a metabolic insight into the effect of NAC on hepatocytes. It is
likely that the impact of NAC on metabolic alterations is underpinned by its ability to
preserve basal and substrate respiration thus allowing constant NADH oxidation
reducing NADH/NAD+ ratio. As discussed previously, the reduction in ketogenesis
and glucose formation with NAC exemplifies the importance of continuing respiration
in preserving the flux of acetyl-coA into the TCA cycle. It is likely that the antioxidant
effects of NAC protect the respiratory chain components from ROS injury.
Furthermore, a novel finding of this study is that both NAC and the antioxidant, CX-
tocopherol, induced uncoupled respiration. The effect of these antioxidants on
uncoupled respiration has not been previously shown. The extent of uncoupled
respiration induced was modest and could not account for the entire recovery in
respiration with NAC. However, increased uncoupled respiration with NAC can
potentially contribute to several observations made in this present study. First, the
proton leaks associated with the uncoupling process can contribute to the lower
mitochondrial membrane potential. Second, it may have impeded the rise in
compensatory respiration in the presence ofDNP.
Although these antioxidants did not reverse the mitochondrial impairment that occurred
in the presence of DNP, the role of oxidative stress in modulating cell respiration under
this condition cannot be excluded for two potential reasons. First, the uncoupling
process induced by these antioxidants can lead to a reduction in ROS formation.
Second, neither NAC nor a-tocopherol is a mitochondrial-targeted antioxidant, which
can accumulate at a higher concentration within mitochondrial matrix. NAC, a
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glutathione precursor, is a powerful scavenger of hypochlorous acid (H-OC1) and
hydrogen peroxide (HjO^), but its reaction with superoxide within the mitochondrial
matrix remains unclear (163, 164).
There have been many studies that demonstrate beneficial effect of NAC in
counteracting oxidative stress (126, 165, 166). However, the ability of NAC to induce
uncoupling of respiration in this present study raises the question whether ATP
formation would be compromised with prolonged treatment. Prolonged NAC
treatment in paracetamol-induced liver necrosis has been shown to impair liver
regeneration (167). We did not determine the impact of NAC on ATP homeostasis in
this study.
Not allfatty acids are equal
Finally, our data highlight the differences between oleate and octanoate. The differences
are largely stemmed from their disparity in (3-oxidation (101, 168). The rate of |3-
oxidation for oleate is limited by CPT1, an enzyme responsible for its transport across
the mitochondrial membrane (169). Thus, oleate is channeled towards esterification. By
comparison, the ease of octanoate to diffuse into the mitochondria independent of
CPT1 results in a partitioning towards oxidation rather than esterification. Enhanced
lipolysis with octanoate has led to the proposal that medium chain fatty acids are
beneficial in promoting weight loss and preserving insulin sensitivity (102, 103). The
perceived beneficial effects however are tissue specific; despite decreased adiposity and
enhanced insulin sensitivity in muscle and adipose tissue, MCFA promote steatosis and
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insulin resistance in the liver (170).
LPON demonstrates the impact of octanoate on hepatocytes that are already burdened
by excessive energy substrates. Efficient |3-oxidation with octanoate yields higher
ketogenesis hence increased acetyl-coA, which in turn, decreases glucose oxidation
(despite preserved mitochondrial function), as well as promotes de novo lipogenesis as
evidenced by increased triglyceride over the period of treatment. In the presence of
increased energy substrates such as seen with LPON, these effects are augmented.
Moreover, other energy substrates synergize with octanoate culminating in
overwhelmed mitochondrial (1-oxidation. This leads to the induction of to- and
peroxisomal |3-oxidation as evidenced by increased acyl carnitines and dicarboxylic acid
formation. These pathways generate a considerable amount of ROS and have been
implicated in the progression from steatosis to steatohepatitis (157).
limitations andfuture direction
Several limitations have to be acknowledged. These studies were focused specifically on
hepatocytes in vitro. Therefore, the involvement of adipokines was not examined. Future
in vitro studies should include the impact of LPON on insulin signaling, ATP
homeostasis and lipid droplets dynamics. Our data have highlighted several interesting
observations that can be translated into clinical research. For example, the role of
incomplete fatty acid oxidation in the progression of steatohepatitis and fibrosis deserve
further evaluation. The concentration of dicarboxylic acids and acyl carnitine can be
measured in vivo as a marker of incomplete fatty acid oxidation. Similarly, the correlation
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between TCA cycle activity and clinical stages of NAFLD is yet to be established. There
are many studies examining mitochondrial impairment in human NAFLD. Few,
however, are focused on the events leading to its development.
Conclusion
In summary, our data suggest that hepatic steatosis per se does not have direct impact on
mitochondrial function; nor does it influence glucose metabolism. It is simply a marker
of deranged metabolic milieu. In contrast, ROS is a determinant of mitochondrial
function in the long term. It is likely that ROS act as energy sensor providing the
impetus to metabolic adaptations gearing towards limiting further ROS production.
Such adaptations would include curtailing energy substrate flux into TCA cycle, thus
acetyl-coA has to be diverted towards other pathways including ketogenesis and de novo
lipogenesis. However, a critical juncture would be reached if the surge of energy
substrates were to continue. The metabolic adaptations and antioxidants would no
longer able to cope with excessive ROS formation. In this milieu, further ROS
formation triggers a vicious cycle including cascades of proinflammatory cytokine
culminating in the onset of changes that lead to steatohepatitis and fibrosis (55). Thus,
reduction in cellular steatosis is not always the desired outcome without concomitant
reduction in energy substrate and ROS formation. The results of this study would
support strategies focused on establishing the balance between excessive ROS
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Supplementary data 1: Confirming the presence of insulin receptor in C3A cells
51.1. Introduction
Our aim was to confirm that insulin receptors are present in treated C3A cells.
51.2. Methods
Sl.2.1. Immunohistochemistry
Immunohistochemistry was performed to confirm the presence of insulin receptors on
C3A cells. C3A and HepG2 cells (positive control) were grown in chamber slides until
70% confluence. Slides were fixed using 4% paraformaldehyde and rinsed in PBS before
5-minute incubation in hydrogen peroxide. Insulin receptor antibody (120fil at the
following concentrations: 1:25, 1:50, 1:100) was added to the designated chamber and
was allowed to incubate overnight at 4°C. A separate slide was incubated with IgG as
negative control. Slides were then rinsed and incubated with labeled polymer-HRP anti
mouse as the secondary antibody for 40 minutes. DAB chromogen solution (200pl) was
then applied to each slide for 5 minutes. Slides were then washed, counterstained with
haematoxylin, dehydrated using alcohols (from 50 to 100%) and mounted. The slides
were viewed under light microscopy and photographed. The stained area was quantified
using ImageJ. Briefly, the images were set to a threshold to highlight stained area and
analysed using 'analyze particle' function of the ImageJ.
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S1.3. Results
Sl.3.1. Insulin receptors are present in C3A cells
Figure Sl.3.1 shows representative images of slides from the immunohistochemistry
studies. The dark brown staining of insulin receptors was present in C3A cells and
appeared to be comparable to that seen with HepG2 cells (positive control).
Next, we examined whether insulin receptors remained present in C3A cells after a 72-
hour treatment with LPON. Figure SI.3.2 Panel A and B are representative images of
LPON treated cells following incubation with anti-(3 subunit of insulin receptor
(dilution 1:100). Insulin receptors remained detectable after LPON treatment.
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Figure Sl.3.1. Insulin receptors are present in C3A cells.
C3A cells were grown in two-chamber slides until 70% confluent. Cells were not treated
with energy substrates but were grown for further 72 hours. Anti-|3 subunit of insulin
receptor was used as the primary antibody (described in section 1.2.1). Insulin receptors
were stained dark brown in the presence of anti-|3 subunit of insulin receptor antibody.
A, C3A cells with 1:25 primary antibody; B, C3A cells with 1:50 primary antibody; C,
C3A cells with 1:100; D, C3A cells without primary antibody; E, C3A cells with IgG
(negative control); F, HepG2 (positive control).
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Figure Sl.3.2. Insulin receptors in C3A cells treated with LPON.
C3A cells were grown and treated in two chamber slides until 70% confluent for 72
hours before immunohistochemistry using anti-[3 subunit of insulin receptor (diluted to
1:100) as the primary antibody. A, Untreated; B, LPON; C, LP; D, Octanoate.
Magnification x20.
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Supplementary data 2: Determining the optimal concentration of insulin
52.1. Introduction
Dose response curve using insulin concentration (0-75nM) was performed to determine
the optimal concentration of insulin for subsequent experiments.
52.2. Methods
S2.2.1. Insulin dose response curve
Cells were grown and treated with LPON in 6-well plate as previously described in
section 2.1.1. FBS was removed 24 hour prior to experimentation. MEME (without
FBS) was then aspirated; cells were then rinsed before a 4-hour incubation with insulin
at the specified concentrations. Glucose flux in the incubation medium was determined
using the method described in section 9.2.2 of the main text.
52.3. Results
S2.3.1. Insulin dose response curve to determine optimal insulin concentration
As demonstrated in Figure S2.3.1, maximal reduction of endogenous glucose flux
formation was attained at lOnM of insulin. Interestingly, there was a dose dependent
increase in glucose with subsequent concentrations of insulin. Indeed, a dramatic rise in
glucose was observed with 75nM of insulin.
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Figure S2.3.1. Dose response curve with insulin (0-75nM).
Untreated C3A cells were grown in MEME with FBS until 70% confluent. Cells were
incubated for further 72 hours. FBS were then removed and cells were left in MEME
culture medium for another 72 hours. Cells were rinsed before a 4-hour incubation of
insulin without exogenous glucose. Data are presented as mean ± SEM; P<0.0001,
*P<0.05.
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